2 Dirt-Cheap Value Stocks to Buy Now

Motley Fool2022-01-30

Growth stocks, on balance, have dramatically outperformed value stocks since the last major financial crisis. Historically low federal fund rates (the rate at which banks lend to one another), ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

908

Report

Comment（71）

Blading23
·2022-02-01
Read
Reply
1
Report
Fold Replies
- Blading23:
  like
  2022-02-01
  Reply
  Report
Steven Tay
·2022-01-31
OK
Reply
1
Report
PEPESZ
·2022-01-31
[Smile] [Smile] [Smile] [Smile]
Reply
2
Report
JamesfromSG
·2022-01-31
Ok
Reply
2
Report
John22
·2022-01-31
True
Reply
2
Report
HH浩
·2022-01-31
Cheapness based on dividend alone is not asound strategy as dividend come from the profit and sustainability of profit is most important to gauge whether it is a valued buy or not.
Reply
Like
Report
Gneiss
·2022-01-31
Thank you for this
Reply
1
Report
SCLIEW
·2022-01-31
666
Reply
2
Report
Huat Huat Ah
·2022-01-31
Huat huat all
Reply
3
Report
Jess261
·2022-01-31
Okay
Reply
1
Report
Jazim
·2022-01-31
Okay
Reply
3
Report
Nasbhai
·2022-01-31
Still find it over-valued in a way though
Reply
3
Report
seejay
·2022-01-31
Watchlist
Reply
6
Report
Aaronboy
·2022-01-31
Good buy
Reply
5
Report
Ccchia
·2022-01-31
Good
Reply
4
Report
逢場作戲又一日
·2022-01-31
Great
Reply
2
Report
jojoc
·2022-01-31
Ok
Reply
3
Report
Rick13
·2022-01-31
Good
Reply
2
Report
MNCoffee
·2022-01-31
wow
Reply
2
Report
ckLai
·2022-01-31
Hi
Reply
2
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/1191140677?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-01-30 10:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1191140677","market":"us","top_or_hot":-1,"title":"2 Dirt-Cheap Value Stocks to Buy Now","media":"Motley Fool","content":"<div>\n<p>Growth stocks, on balance, have dramatically outperformed value stocks since the last major financial crisis. Historically low federal fund rates (the rate at which banks lend to one another), ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/29/2-dirt-cheap-value-stocks-to-buy-now/\">Source Link</a>\n\n</div>\n","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Dirt-Cheap Value Stocks to Buy Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Dirt-Cheap Value Stocks to Buy Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-30 10:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/29/2-dirt-cheap-value-stocks-to-buy-now/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Growth stocks, on balance, have dramatically outperformed value stocks since the last major financial crisis. Historically low federal fund rates (the rate at which banks lend to one another), ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/29/2-dirt-cheap-value-stocks-to-buy-now/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TAK","symbol_name":"武田制药","start_time":0,"source_url":"https://www.fool.com/investing/2022/01/29/2-dirt-cheap-value-stocks-to-buy-now/","article_id":"1191140677","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1191140677","pubTimestamp":1643509277,"columns":[],"sourceInfo":null,"weMediaInfo":null,"summary":"Growth stocks, on balance, have dramatically outperformed value stocks since the last major financia","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"TAK":"武田制药","VTRS":"Viatris Inc."},"translate_title":"现在买2只非常便宜的价值股票","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TAK":0.9,"VTRS":0.9},"content_text":"Growth stocks, on balance, have dramatically outperformed value stocks since the last major financial crisis. Historically low federal fund rates (the rate at which banks lend to one another), combined with enormous levels of fiscal stimulus by the U.S. government, were the main drivers behind this unprecedented 14-year-long bull run in growth stocks.But with the Federal Reserve poised to roll out a series of interest rate hikes this year, value stocks are probably going to outperform growth stocks for the foreseeable future. In fact, value stocks have already started trouncing growth stocks, in terms of their total return on capital, since the beginning of the fourth quarter of 2021.With this powerful trend reversal in mind, investors may want to load up on high-quality value stocks during the opening weeks of 2022. Which value plays are the best buys right now? The dividend-paying pharmaceutical stocks Takeda Pharmaceutical and Viatris are both currently trading at dirt-cheap valuations. Here's why investors may want to add these two drugmakers to their portfolios soon.Takeda Pharmaceutical: An incredibly cheap high-yield dividend stockJapanese pharma giant Takeda was one of the few major drug manufacturers to lose ground during the 14-year-long bull market. Various clinical setbacks, upcoming patent expiries, a highly leveraged balance sheet due to itsacquisitionof the rare disease specialist Shire, and a lack of a franchise-level medication all weighed on its shares during this period. Takeda's shares, in fact, have lost almost a third of their value in just the past three years. However, the company's stock now appears primed for a major reversal for three key reasons.First off, Takeda's Wave 1 clinical pipeline has started to generate some truly high-value commercial products recently. Late last year, for instance, the company scored two important U.S. regulatory approvals for the post-transplant cytomegalovirus infection drug Livtencity and the niche lung cancer medication Exkivity. Takeda believes these two drugs will help drive respectable levels of top-line growth all the way out to fiscal year 2030 and keep its ongoing deleveraging process on track.Second, Takeda's stock is presently trading at 1.5 times fiscal year 2022 projected sales. That's easily one of the lower price-to-sales ratios in the major drug manufacturing space right now. Takeda, in effect, is a bona fide value stock. This ought to benefit the drugmaker's share price in the current value-oriented market.Third, Takeda pays out a sky-high annualized dividend yield of 5.6% right now. The company's stellar yield is also well-funded, evinced by its fairly low payout ratio of 59.4%.All told, Takeda's stock ought to shine as investors rotate into pure-play value stocks and away from riskier growth equities.Viatris: Stability and a top dividend yieldViatris is a generic and biosimilar drug company. Since itsformationa little over a year ago, the company's shares have fallen by over 10.4%. Viatris' stock has so farfailed to exciteinvestors due to itsdebt-laden balance sheet, lack of clear-cut growth products, and rather modest long-term outlook. The company, after all, isn't expecting sustainable top-line growth until 2024.Despite these headwinds, however, Viatris stock should appeal to investors with an eye toward value. The long and short of it is that Viatris' stock is among the absolute cheapest within the realm of dividend-paying pharma stocks right now. Underscoring this point, the drugmaker's shares are presently trading at less than one time forward-looking sales. What's more, Viatris currently offers shareholders an above-average yield -- relative to its peer group -- of 3.29% on an annualized basis.So while Viatris stock isn't going to make shareholders rich anytime soon, this pharma stock does come across as a highly safe investing vehicle, thanks to its bargain bin valuation and attractive dividend yield. And Viatris' top-notch margin of safety should prove to be a winning feature in this risk-averse market.","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":633966907,"gmtCreate":1643684875444,"gmtModify":1676532670099,"author":{"id":"3565700003213382","authorId":"3565700003213382","name":"Blading23","avatar":"https://community-static.tradeup.com/news/4cd7ba668d1c755bf79285b205abdfb2","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3565700003213382","authorIdStr":"3565700003213382"},"htmlText":"Read","listText":"Read","text":"Read","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/633966907","repostId":1191140677,"repostType":4,"repost":{"id":"1191140677","kind":"news","pubTimestamp":1643509277,"share":"https://ttm.financial/m/news/1191140677?lang=&edition=fundamental","pubTime":"2022-01-30 10:21","market":"us","language":"en","title":"2 Dirt-Cheap Value Stocks to Buy Now","url":"https://stock-news.laohu8.com/highlight/detail?id=1191140677","media":"Motley Fool","summary":"Growth stocks, on balance, have dramatically outperformed value stocks since the last major financia","content":"<html><head></head><body><p>Growth stocks, on balance, have dramatically outperformed value stocks since the last major financial crisis. Historically low federal fund rates (the rate at which banks lend to one another), combined with enormous levels of fiscal stimulus by the U.S. government, were the main drivers behind this unprecedented 14-year-long bull run in growth stocks.</p><p>But with the Federal Reserve poised to roll out a series of interest rate hikes this year, value stocks are probably going to outperform growth stocks for the foreseeable future. In fact, value stocks have already started trouncing growth stocks, in terms of their total return on capital, since the beginning of the fourth quarter of 2021.</p><p>With this powerful trend reversal in mind, investors may want to load up on high-quality value stocks during the opening weeks of 2022. Which value plays are the best buys right now? The dividend-paying pharmaceutical stocks <a href=\"https://laohu8.com/S/TAK\"><b>Takeda Pharmaceutical</b></a> and <a href=\"https://laohu8.com/S/VTRS\"><b>Viatris</b></a> are both currently trading at dirt-cheap valuations. Here&#39;s why investors may want to add these two drugmakers to their portfolios soon.</p><p><a href=\"https://laohu8.com/S/TAK\"><b>Takeda Pharmaceutical</b></a>: An incredibly cheap high-yield dividend stock</p><p>Japanese pharma giant Takeda was one of the few major drug manufacturers to lose ground during the 14-year-long bull market. Various clinical setbacks, upcoming patent expiries, a highly leveraged balance sheet due to itsacquisitionof the rare disease specialist Shire, and a lack of a franchise-level medication all weighed on its shares during this period. Takeda&#39;s shares, in fact, have lost almost a third of their value in just the past three years. However, the company&#39;s stock now appears primed for a major reversal for three key reasons.</p><p>First off, Takeda&#39;s Wave 1 clinical pipeline has started to generate some truly high-value commercial products recently. Late last year, for instance, the company scored two important U.S. regulatory approvals for the post-transplant cytomegalovirus infection drug Livtencity and the niche lung cancer medication Exkivity. Takeda believes these two drugs will help drive respectable levels of top-line growth all the way out to fiscal year 2030 and keep its ongoing deleveraging process on track.</p><p>Second, Takeda&#39;s stock is presently trading at 1.5 times fiscal year 2022 projected sales. That&#39;s easily one of the lower price-to-sales ratios in the major drug manufacturing space right now. Takeda, in effect, is a bona fide value stock. This ought to benefit the drugmaker&#39;s share price in the current value-oriented market.</p><p>Third, Takeda pays out a sky-high annualized dividend yield of 5.6% right now. The company&#39;s stellar yield is also well-funded, evinced by its fairly low payout ratio of 59.4%.</p><p>All told, Takeda&#39;s stock ought to shine as investors rotate into pure-play value stocks and away from riskier growth equities.</p><p><a href=\"https://laohu8.com/S/VTRS\"><b>Viatris</b></a>: Stability and a top dividend yield</p><p>Viatris is a generic and biosimilar drug company. Since itsformationa little over a year ago, the company&#39;s shares have fallen by over 10.4%. Viatris&#39; stock has so farfailed to exciteinvestors due to itsdebt-laden balance sheet, lack of clear-cut growth products, and rather modest long-term outlook. The company, after all, isn&#39;t expecting sustainable top-line growth until 2024.</p><p>Despite these headwinds, however, Viatris stock should appeal to investors with an eye toward value. The long and short of it is that Viatris&#39; stock is among the absolute cheapest within the realm of dividend-paying pharma stocks right now. Underscoring this point, the drugmaker&#39;s shares are presently trading at less than one time forward-looking sales. What&#39;s more, Viatris currently offers shareholders an above-average yield -- relative to its peer group -- of 3.29% on an annualized basis.</p><p>So while Viatris stock isn&#39;t going to make shareholders rich anytime soon, this pharma stock does come across as a highly safe investing vehicle, thanks to its bargain bin valuation and attractive dividend yield. And Viatris&#39; top-notch margin of safety should prove to be a winning feature in this risk-averse market.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Dirt-Cheap Value Stocks to Buy Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Dirt-Cheap Value Stocks to Buy Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-30 10:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/29/2-dirt-cheap-value-stocks-to-buy-now/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Growth stocks, on balance, have dramatically outperformed value stocks since the last major financial crisis. Historically low federal fund rates (the rate at which banks lend to one another), ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/29/2-dirt-cheap-value-stocks-to-buy-now/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VTRS":"Viatris Inc.","TAK":"武田制药"},"source_url":"https://www.fool.com/investing/2022/01/29/2-dirt-cheap-value-stocks-to-buy-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1191140677","content_text":"Growth stocks, on balance, have dramatically outperformed value stocks since the last major financial crisis. Historically low federal fund rates (the rate at which banks lend to one another), combined with enormous levels of fiscal stimulus by the U.S. government, were the main drivers behind this unprecedented 14-year-long bull run in growth stocks.But with the Federal Reserve poised to roll out a series of interest rate hikes this year, value stocks are probably going to outperform growth stocks for the foreseeable future. In fact, value stocks have already started trouncing growth stocks, in terms of their total return on capital, since the beginning of the fourth quarter of 2021.With this powerful trend reversal in mind, investors may want to load up on high-quality value stocks during the opening weeks of 2022. Which value plays are the best buys right now? The dividend-paying pharmaceutical stocks Takeda Pharmaceutical and Viatris are both currently trading at dirt-cheap valuations. Here's why investors may want to add these two drugmakers to their portfolios soon.Takeda Pharmaceutical: An incredibly cheap high-yield dividend stockJapanese pharma giant Takeda was one of the few major drug manufacturers to lose ground during the 14-year-long bull market. Various clinical setbacks, upcoming patent expiries, a highly leveraged balance sheet due to itsacquisitionof the rare disease specialist Shire, and a lack of a franchise-level medication all weighed on its shares during this period. Takeda's shares, in fact, have lost almost a third of their value in just the past three years. However, the company's stock now appears primed for a major reversal for three key reasons.First off, Takeda's Wave 1 clinical pipeline has started to generate some truly high-value commercial products recently. Late last year, for instance, the company scored two important U.S. regulatory approvals for the post-transplant cytomegalovirus infection drug Livtencity and the niche lung cancer medication Exkivity. Takeda believes these two drugs will help drive respectable levels of top-line growth all the way out to fiscal year 2030 and keep its ongoing deleveraging process on track.Second, Takeda's stock is presently trading at 1.5 times fiscal year 2022 projected sales. That's easily one of the lower price-to-sales ratios in the major drug manufacturing space right now. Takeda, in effect, is a bona fide value stock. This ought to benefit the drugmaker's share price in the current value-oriented market.Third, Takeda pays out a sky-high annualized dividend yield of 5.6% right now. The company's stellar yield is also well-funded, evinced by its fairly low payout ratio of 59.4%.All told, Takeda's stock ought to shine as investors rotate into pure-play value stocks and away from riskier growth equities.Viatris: Stability and a top dividend yieldViatris is a generic and biosimilar drug company. Since itsformationa little over a year ago, the company's shares have fallen by over 10.4%. Viatris' stock has so farfailed to exciteinvestors due to itsdebt-laden balance sheet, lack of clear-cut growth products, and rather modest long-term outlook. The company, after all, isn't expecting sustainable top-line growth until 2024.Despite these headwinds, however, Viatris stock should appeal to investors with an eye toward value. The long and short of it is that Viatris' stock is among the absolute cheapest within the realm of dividend-paying pharma stocks right now. Underscoring this point, the drugmaker's shares are presently trading at less than one time forward-looking sales. What's more, Viatris currently offers shareholders an above-average yield -- relative to its peer group -- of 3.29% on an annualized basis.So while Viatris stock isn't going to make shareholders rich anytime soon, this pharma stock does come across as a highly safe investing vehicle, thanks to its bargain bin valuation and attractive dividend yield. And Viatris' top-notch margin of safety should prove to be a winning feature in this risk-averse market.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":7223225,"gmtCreate":1643684881453,"gmtModify":1663239708526,"authorId":3565700003213382,"author":{"id":3565700003213382,"idStr":"3565700003213382","authorId":3565700003213382,"name":"Blading23","avatar":"https://community-static.tradeup.com/news/4cd7ba668d1c755bf79285b205abdfb2","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":633966907,"type":1,"supId":0,"prevId":0,"content":"<u>like</u>","text":"<u>like</u>","html":"<u>like</u>"}],"langContent":"CN"},{"id":9093668298,"gmtCreate":1643613433058,"gmtModify":1676533836167,"author":{"id":"4099285253763630","authorId":"4099285253763630","name":"Steven Tay","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"4099285253763630","authorIdStr":"4099285253763630"},"htmlText":"OK&nbsp;","listText":"OK&nbsp;","text":"OK","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093668298","repostId":1191140677,"repostType":4,"repost":{"id":"1191140677","kind":"news","pubTimestamp":1643509277,"share":"https://ttm.financial/m/news/1191140677?lang=&edition=fundamental","pubTime":"2022-01-30 10:21","market":"us","language":"en","title":"2 Dirt-Cheap Value Stocks to Buy Now","url":"https://stock-news.laohu8.com/highlight/detail?id=1191140677","media":"Motley Fool","summary":"Growth stocks, on balance, have dramatically outperformed value stocks since the last major financia","content":"<html><head></head><body><p>Growth stocks, on balance, have dramatically outperformed value stocks since the last major financial crisis. Historically low federal fund rates (the rate at which banks lend to one another), combined with enormous levels of fiscal stimulus by the U.S. government, were the main drivers behind this unprecedented 14-year-long bull run in growth stocks.</p><p>But with the Federal Reserve poised to roll out a series of interest rate hikes this year, value stocks are probably going to outperform growth stocks for the foreseeable future. In fact, value stocks have already started trouncing growth stocks, in terms of their total return on capital, since the beginning of the fourth quarter of 2021.</p><p>With this powerful trend reversal in mind, investors may want to load up on high-quality value stocks during the opening weeks of 2022. Which value plays are the best buys right now? The dividend-paying pharmaceutical stocks <a href=\"https://laohu8.com/S/TAK\"><b>Takeda Pharmaceutical</b></a> and <a href=\"https://laohu8.com/S/VTRS\"><b>Viatris</b></a> are both currently trading at dirt-cheap valuations. Here&#39;s why investors may want to add these two drugmakers to their portfolios soon.</p><p><a href=\"https://laohu8.com/S/TAK\"><b>Takeda Pharmaceutical</b></a>: An incredibly cheap high-yield dividend stock</p><p>Japanese pharma giant Takeda was one of the few major drug manufacturers to lose ground during the 14-year-long bull market. Various clinical setbacks, upcoming patent expiries, a highly leveraged balance sheet due to itsacquisitionof the rare disease specialist Shire, and a lack of a franchise-level medication all weighed on its shares during this period. Takeda&#39;s shares, in fact, have lost almost a third of their value in just the past three years. However, the company&#39;s stock now appears primed for a major reversal for three key reasons.</p><p>First off, Takeda&#39;s Wave 1 clinical pipeline has started to generate some truly high-value commercial products recently. Late last year, for instance, the company scored two important U.S. regulatory approvals for the post-transplant cytomegalovirus infection drug Livtencity and the niche lung cancer medication Exkivity. Takeda believes these two drugs will help drive respectable levels of top-line growth all the way out to fiscal year 2030 and keep its ongoing deleveraging process on track.</p><p>Second, Takeda&#39;s stock is presently trading at 1.5 times fiscal year 2022 projected sales. That&#39;s easily one of the lower price-to-sales ratios in the major drug manufacturing space right now. Takeda, in effect, is a bona fide value stock. This ought to benefit the drugmaker&#39;s share price in the current value-oriented market.</p><p>Third, Takeda pays out a sky-high annualized dividend yield of 5.6% right now. The company&#39;s stellar yield is also well-funded, evinced by its fairly low payout ratio of 59.4%.</p><p>All told, Takeda&#39;s stock ought to shine as investors rotate into pure-play value stocks and away from riskier growth equities.</p><p><a href=\"https://laohu8.com/S/VTRS\"><b>Viatris</b></a>: Stability and a top dividend yield</p><p>Viatris is a generic and biosimilar drug company. Since itsformationa little over a year ago, the company&#39;s shares have fallen by over 10.4%. Viatris&#39; stock has so farfailed to exciteinvestors due to itsdebt-laden balance sheet, lack of clear-cut growth products, and rather modest long-term outlook. The company, after all, isn&#39;t expecting sustainable top-line growth until 2024.</p><p>Despite these headwinds, however, Viatris stock should appeal to investors with an eye toward value. The long and short of it is that Viatris&#39; stock is among the absolute cheapest within the realm of dividend-paying pharma stocks right now. Underscoring this point, the drugmaker&#39;s shares are presently trading at less than one time forward-looking sales. What&#39;s more, Viatris currently offers shareholders an above-average yield -- relative to its peer group -- of 3.29% on an annualized basis.</p><p>So while Viatris stock isn&#39;t going to make shareholders rich anytime soon, this pharma stock does come across as a highly safe investing vehicle, thanks to its bargain bin valuation and attractive dividend yield. And Viatris&#39; top-notch margin of safety should prove to be a winning feature in this risk-averse market.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Dirt-Cheap Value Stocks to Buy Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Dirt-Cheap Value Stocks to Buy Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-30 10:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/29/2-dirt-cheap-value-stocks-to-buy-now/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Growth stocks, on balance, have dramatically outperformed value stocks since the last major financial crisis. Historically low federal fund rates (the rate at which banks lend to one another), ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/29/2-dirt-cheap-value-stocks-to-buy-now/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VTRS":"Viatris Inc.","TAK":"武田制药"},"source_url":"https://www.fool.com/investing/2022/01/29/2-dirt-cheap-value-stocks-to-buy-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1191140677","content_text":"Growth stocks, on balance, have dramatically outperformed value stocks since the last major financial crisis. Historically low federal fund rates (the rate at which banks lend to one another), combined with enormous levels of fiscal stimulus by the U.S. government, were the main drivers behind this unprecedented 14-year-long bull run in growth stocks.But with the Federal Reserve poised to roll out a series of interest rate hikes this year, value stocks are probably going to outperform growth stocks for the foreseeable future. In fact, value stocks have already started trouncing growth stocks, in terms of their total return on capital, since the beginning of the fourth quarter of 2021.With this powerful trend reversal in mind, investors may want to load up on high-quality value stocks during the opening weeks of 2022. Which value plays are the best buys right now? The dividend-paying pharmaceutical stocks Takeda Pharmaceutical and Viatris are both currently trading at dirt-cheap valuations. Here's why investors may want to add these two drugmakers to their portfolios soon.Takeda Pharmaceutical: An incredibly cheap high-yield dividend stockJapanese pharma giant Takeda was one of the few major drug manufacturers to lose ground during the 14-year-long bull market. Various clinical setbacks, upcoming patent expiries, a highly leveraged balance sheet due to itsacquisitionof the rare disease specialist Shire, and a lack of a franchise-level medication all weighed on its shares during this period. Takeda's shares, in fact, have lost almost a third of their value in just the past three years. However, the company's stock now appears primed for a major reversal for three key reasons.First off, Takeda's Wave 1 clinical pipeline has started to generate some truly high-value commercial products recently. Late last year, for instance, the company scored two important U.S. regulatory approvals for the post-transplant cytomegalovirus infection drug Livtencity and the niche lung cancer medication Exkivity. Takeda believes these two drugs will help drive respectable levels of top-line growth all the way out to fiscal year 2030 and keep its ongoing deleveraging process on track.Second, Takeda's stock is presently trading at 1.5 times fiscal year 2022 projected sales. That's easily one of the lower price-to-sales ratios in the major drug manufacturing space right now. Takeda, in effect, is a bona fide value stock. This ought to benefit the drugmaker's share price in the current value-oriented market.Third, Takeda pays out a sky-high annualized dividend yield of 5.6% right now. The company's stellar yield is also well-funded, evinced by its fairly low payout ratio of 59.4%.All told, Takeda's stock ought to shine as investors rotate into pure-play value stocks and away from riskier growth equities.Viatris: Stability and a top dividend yieldViatris is a generic and biosimilar drug company. Since itsformationa little over a year ago, the company's shares have fallen by over 10.4%. Viatris' stock has so farfailed to exciteinvestors due to itsdebt-laden balance sheet, lack of clear-cut growth products, and rather modest long-term outlook. The company, after all, isn't expecting sustainable top-line growth until 2024.Despite these headwinds, however, Viatris stock should appeal to investors with an eye toward value. The long and short of it is that Viatris' stock is among the absolute cheapest within the realm of dividend-paying pharma stocks right now. Underscoring this point, the drugmaker's shares are presently trading at less than one time forward-looking sales. What's more, Viatris currently offers shareholders an above-average yield -- relative to its peer group -- of 3.29% on an annualized basis.So while Viatris stock isn't going to make shareholders rich anytime soon, this pharma stock does come across as a highly safe investing vehicle, thanks to its bargain bin valuation and attractive dividend yield. And Viatris' top-notch margin of safety should prove to be a winning feature in this risk-averse market.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9093686642,"gmtCreate":1643610260424,"gmtModify":1676533835966,"author":{"id":"3578658486074975","authorId":"3578658486074975","name":"PEPESZ","avatar":"https://static.tigerbbs.com/ebaf682b46c1f56e5c38680b33a78d5f","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3578658486074975","authorIdStr":"3578658486074975"},"htmlText":"[Smile]&nbsp;[Smile]&nbsp;[Smile]&nbsp;[Smile]&nbsp;","listText":"[Smile]&nbsp;[Smile]&nbsp;[Smile]&nbsp;[Smile]&nbsp;","text":"[Smile] [Smile] [Smile] [Smile]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093686642","repostId":1191140677,"repostType":4,"repost":{"id":"1191140677","kind":"news","pubTimestamp":1643509277,"share":"https://ttm.financial/m/news/1191140677?lang=&edition=fundamental","pubTime":"2022-01-30 10:21","market":"us","language":"en","title":"2 Dirt-Cheap Value Stocks to Buy Now","url":"https://stock-news.laohu8.com/highlight/detail?id=1191140677","media":"Motley Fool","summary":"Growth stocks, on balance, have dramatically outperformed value stocks since the last major financia","content":"<html><head></head><body><p>Growth stocks, on balance, have dramatically outperformed value stocks since the last major financial crisis. Historically low federal fund rates (the rate at which banks lend to one another), combined with enormous levels of fiscal stimulus by the U.S. government, were the main drivers behind this unprecedented 14-year-long bull run in growth stocks.</p><p>But with the Federal Reserve poised to roll out a series of interest rate hikes this year, value stocks are probably going to outperform growth stocks for the foreseeable future. In fact, value stocks have already started trouncing growth stocks, in terms of their total return on capital, since the beginning of the fourth quarter of 2021.</p><p>With this powerful trend reversal in mind, investors may want to load up on high-quality value stocks during the opening weeks of 2022. Which value plays are the best buys right now? The dividend-paying pharmaceutical stocks <a href=\"https://laohu8.com/S/TAK\"><b>Takeda Pharmaceutical</b></a> and <a href=\"https://laohu8.com/S/VTRS\"><b>Viatris</b></a> are both currently trading at dirt-cheap valuations. Here&#39;s why investors may want to add these two drugmakers to their portfolios soon.</p><p><a href=\"https://laohu8.com/S/TAK\"><b>Takeda Pharmaceutical</b></a>: An incredibly cheap high-yield dividend stock</p><p>Japanese pharma giant Takeda was one of the few major drug manufacturers to lose ground during the 14-year-long bull market. Various clinical setbacks, upcoming patent expiries, a highly leveraged balance sheet due to itsacquisitionof the rare disease specialist Shire, and a lack of a franchise-level medication all weighed on its shares during this period. Takeda&#39;s shares, in fact, have lost almost a third of their value in just the past three years. However, the company&#39;s stock now appears primed for a major reversal for three key reasons.</p><p>First off, Takeda&#39;s Wave 1 clinical pipeline has started to generate some truly high-value commercial products recently. Late last year, for instance, the company scored two important U.S. regulatory approvals for the post-transplant cytomegalovirus infection drug Livtencity and the niche lung cancer medication Exkivity. Takeda believes these two drugs will help drive respectable levels of top-line growth all the way out to fiscal year 2030 and keep its ongoing deleveraging process on track.</p><p>Second, Takeda&#39;s stock is presently trading at 1.5 times fiscal year 2022 projected sales. That&#39;s easily one of the lower price-to-sales ratios in the major drug manufacturing space right now. Takeda, in effect, is a bona fide value stock. This ought to benefit the drugmaker&#39;s share price in the current value-oriented market.</p><p>Third, Takeda pays out a sky-high annualized dividend yield of 5.6% right now. The company&#39;s stellar yield is also well-funded, evinced by its fairly low payout ratio of 59.4%.</p><p>All told, Takeda&#39;s stock ought to shine as investors rotate into pure-play value stocks and away from riskier growth equities.</p><p><a href=\"https://laohu8.com/S/VTRS\"><b>Viatris</b></a>: Stability and a top dividend yield</p><p>Viatris is a generic and biosimilar drug company. Since itsformationa little over a year ago, the company&#39;s shares have fallen by over 10.4%. Viatris&#39; stock has so farfailed to exciteinvestors due to itsdebt-laden balance sheet, lack of clear-cut growth products, and rather modest long-term outlook. The company, after all, isn&#39;t expecting sustainable top-line growth until 2024.</p><p>Despite these headwinds, however, Viatris stock should appeal to investors with an eye toward value. The long and short of it is that Viatris&#39; stock is among the absolute cheapest within the realm of dividend-paying pharma stocks right now. Underscoring this point, the drugmaker&#39;s shares are presently trading at less than one time forward-looking sales. What&#39;s more, Viatris currently offers shareholders an above-average yield -- relative to its peer group -- of 3.29% on an annualized basis.</p><p>So while Viatris stock isn&#39;t going to make shareholders rich anytime soon, this pharma stock does come across as a highly safe investing vehicle, thanks to its bargain bin valuation and attractive dividend yield. And Viatris&#39; top-notch margin of safety should prove to be a winning feature in this risk-averse market.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Dirt-Cheap Value Stocks to Buy Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Dirt-Cheap Value Stocks to Buy Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-30 10:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/29/2-dirt-cheap-value-stocks-to-buy-now/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Growth stocks, on balance, have dramatically outperformed value stocks since the last major financial crisis. Historically low federal fund rates (the rate at which banks lend to one another), ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/29/2-dirt-cheap-value-stocks-to-buy-now/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VTRS":"Viatris Inc.","TAK":"武田制药"},"source_url":"https://www.fool.com/investing/2022/01/29/2-dirt-cheap-value-stocks-to-buy-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1191140677","content_text":"Growth stocks, on balance, have dramatically outperformed value stocks since the last major financial crisis. Historically low federal fund rates (the rate at which banks lend to one another), combined with enormous levels of fiscal stimulus by the U.S. government, were the main drivers behind this unprecedented 14-year-long bull run in growth stocks.But with the Federal Reserve poised to roll out a series of interest rate hikes this year, value stocks are probably going to outperform growth stocks for the foreseeable future. In fact, value stocks have already started trouncing growth stocks, in terms of their total return on capital, since the beginning of the fourth quarter of 2021.With this powerful trend reversal in mind, investors may want to load up on high-quality value stocks during the opening weeks of 2022. Which value plays are the best buys right now? The dividend-paying pharmaceutical stocks Takeda Pharmaceutical and Viatris are both currently trading at dirt-cheap valuations. Here's why investors may want to add these two drugmakers to their portfolios soon.Takeda Pharmaceutical: An incredibly cheap high-yield dividend stockJapanese pharma giant Takeda was one of the few major drug manufacturers to lose ground during the 14-year-long bull market. Various clinical setbacks, upcoming patent expiries, a highly leveraged balance sheet due to itsacquisitionof the rare disease specialist Shire, and a lack of a franchise-level medication all weighed on its shares during this period. Takeda's shares, in fact, have lost almost a third of their value in just the past three years. However, the company's stock now appears primed for a major reversal for three key reasons.First off, Takeda's Wave 1 clinical pipeline has started to generate some truly high-value commercial products recently. Late last year, for instance, the company scored two important U.S. regulatory approvals for the post-transplant cytomegalovirus infection drug Livtencity and the niche lung cancer medication Exkivity. Takeda believes these two drugs will help drive respectable levels of top-line growth all the way out to fiscal year 2030 and keep its ongoing deleveraging process on track.Second, Takeda's stock is presently trading at 1.5 times fiscal year 2022 projected sales. That's easily one of the lower price-to-sales ratios in the major drug manufacturing space right now. Takeda, in effect, is a bona fide value stock. This ought to benefit the drugmaker's share price in the current value-oriented market.Third, Takeda pays out a sky-high annualized dividend yield of 5.6% right now. The company's stellar yield is also well-funded, evinced by its fairly low payout ratio of 59.4%.All told, Takeda's stock ought to shine as investors rotate into pure-play value stocks and away from riskier growth equities.Viatris: Stability and a top dividend yieldViatris is a generic and biosimilar drug company. Since itsformationa little over a year ago, the company's shares have fallen by over 10.4%. Viatris' stock has so farfailed to exciteinvestors due to itsdebt-laden balance sheet, lack of clear-cut growth products, and rather modest long-term outlook. The company, after all, isn't expecting sustainable top-line growth until 2024.Despite these headwinds, however, Viatris stock should appeal to investors with an eye toward value. The long and short of it is that Viatris' stock is among the absolute cheapest within the realm of dividend-paying pharma stocks right now. Underscoring this point, the drugmaker's shares are presently trading at less than one time forward-looking sales. What's more, Viatris currently offers shareholders an above-average yield -- relative to its peer group -- of 3.29% on an annualized basis.So while Viatris stock isn't going to make shareholders rich anytime soon, this pharma stock does come across as a highly safe investing vehicle, thanks to its bargain bin valuation and attractive dividend yield. And Viatris' top-notch margin of safety should prove to be a winning feature in this risk-averse market.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9093635418,"gmtCreate":1643604874071,"gmtModify":1676533835594,"author":{"id":"4090044065782350","authorId":"4090044065782350","name":"JamesfromSG","avatar":"https://static.tigerbbs.com/d251750cfb493127443c3b9990000f69","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"4090044065782350","authorIdStr":"4090044065782350"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093635418","repostId":1191140677,"repostType":4,"repost":{"id":"1191140677","kind":"news","pubTimestamp":1643509277,"share":"https://ttm.financial/m/news/1191140677?lang=&edition=fundamental","pubTime":"2022-01-30 10:21","market":"us","language":"en","title":"2 Dirt-Cheap Value Stocks to Buy Now","url":"https://stock-news.laohu8.com/highlight/detail?id=1191140677","media":"Motley Fool","summary":"Growth stocks, on balance, have dramatically outperformed value stocks since the last major financia","content":"<html><head></head><body><p>Growth stocks, on balance, have dramatically outperformed value stocks since the last major financial crisis. Historically low federal fund rates (the rate at which banks lend to one another), combined with enormous levels of fiscal stimulus by the U.S. government, were the main drivers behind this unprecedented 14-year-long bull run in growth stocks.</p><p>But with the Federal Reserve poised to roll out a series of interest rate hikes this year, value stocks are probably going to outperform growth stocks for the foreseeable future. In fact, value stocks have already started trouncing growth stocks, in terms of their total return on capital, since the beginning of the fourth quarter of 2021.</p><p>With this powerful trend reversal in mind, investors may want to load up on high-quality value stocks during the opening weeks of 2022. Which value plays are the best buys right now? The dividend-paying pharmaceutical stocks <a href=\"https://laohu8.com/S/TAK\"><b>Takeda Pharmaceutical</b></a> and <a href=\"https://laohu8.com/S/VTRS\"><b>Viatris</b></a> are both currently trading at dirt-cheap valuations. Here&#39;s why investors may want to add these two drugmakers to their portfolios soon.</p><p><a href=\"https://laohu8.com/S/TAK\"><b>Takeda Pharmaceutical</b></a>: An incredibly cheap high-yield dividend stock</p><p>Japanese pharma giant Takeda was one of the few major drug manufacturers to lose ground during the 14-year-long bull market. Various clinical setbacks, upcoming patent expiries, a highly leveraged balance sheet due to itsacquisitionof the rare disease specialist Shire, and a lack of a franchise-level medication all weighed on its shares during this period. Takeda&#39;s shares, in fact, have lost almost a third of their value in just the past three years. However, the company&#39;s stock now appears primed for a major reversal for three key reasons.</p><p>First off, Takeda&#39;s Wave 1 clinical pipeline has started to generate some truly high-value commercial products recently. Late last year, for instance, the company scored two important U.S. regulatory approvals for the post-transplant cytomegalovirus infection drug Livtencity and the niche lung cancer medication Exkivity. Takeda believes these two drugs will help drive respectable levels of top-line growth all the way out to fiscal year 2030 and keep its ongoing deleveraging process on track.</p><p>Second, Takeda&#39;s stock is presently trading at 1.5 times fiscal year 2022 projected sales. That&#39;s easily one of the lower price-to-sales ratios in the major drug manufacturing space right now. Takeda, in effect, is a bona fide value stock. This ought to benefit the drugmaker&#39;s share price in the current value-oriented market.</p><p>Third, Takeda pays out a sky-high annualized dividend yield of 5.6% right now. The company&#39;s stellar yield is also well-funded, evinced by its fairly low payout ratio of 59.4%.</p><p>All told, Takeda&#39;s stock ought to shine as investors rotate into pure-play value stocks and away from riskier growth equities.</p><p><a href=\"https://laohu8.com/S/VTRS\"><b>Viatris</b></a>: Stability and a top dividend yield</p><p>Viatris is a generic and biosimilar drug company. Since itsformationa little over a year ago, the company&#39;s shares have fallen by over 10.4%. Viatris&#39; stock has so farfailed to exciteinvestors due to itsdebt-laden balance sheet, lack of clear-cut growth products, and rather modest long-term outlook. The company, after all, isn&#39;t expecting sustainable top-line growth until 2024.</p><p>Despite these headwinds, however, Viatris stock should appeal to investors with an eye toward value. The long and short of it is that Viatris&#39; stock is among the absolute cheapest within the realm of dividend-paying pharma stocks right now. Underscoring this point, the drugmaker&#39;s shares are presently trading at less than one time forward-looking sales. What&#39;s more, Viatris currently offers shareholders an above-average yield -- relative to its peer group -- of 3.29% on an annualized basis.</p><p>So while Viatris stock isn&#39;t going to make shareholders rich anytime soon, this pharma stock does come across as a highly safe investing vehicle, thanks to its bargain bin valuation and attractive dividend yield. And Viatris&#39; top-notch margin of safety should prove to be a winning feature in this risk-averse market.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Dirt-Cheap Value Stocks to Buy Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Dirt-Cheap Value Stocks to Buy Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-30 10:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/29/2-dirt-cheap-value-stocks-to-buy-now/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Growth stocks, on balance, have dramatically outperformed value stocks since the last major financial crisis. Historically low federal fund rates (the rate at which banks lend to one another), ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/29/2-dirt-cheap-value-stocks-to-buy-now/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VTRS":"Viatris Inc.","TAK":"武田制药"},"source_url":"https://www.fool.com/investing/2022/01/29/2-dirt-cheap-value-stocks-to-buy-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1191140677","content_text":"Growth stocks, on balance, have dramatically outperformed value stocks since the last major financial crisis. Historically low federal fund rates (the rate at which banks lend to one another), combined with enormous levels of fiscal stimulus by the U.S. government, were the main drivers behind this unprecedented 14-year-long bull run in growth stocks.But with the Federal Reserve poised to roll out a series of interest rate hikes this year, value stocks are probably going to outperform growth stocks for the foreseeable future. In fact, value stocks have already started trouncing growth stocks, in terms of their total return on capital, since the beginning of the fourth quarter of 2021.With this powerful trend reversal in mind, investors may want to load up on high-quality value stocks during the opening weeks of 2022. Which value plays are the best buys right now? The dividend-paying pharmaceutical stocks Takeda Pharmaceutical and Viatris are both currently trading at dirt-cheap valuations. Here's why investors may want to add these two drugmakers to their portfolios soon.Takeda Pharmaceutical: An incredibly cheap high-yield dividend stockJapanese pharma giant Takeda was one of the few major drug manufacturers to lose ground during the 14-year-long bull market. Various clinical setbacks, upcoming patent expiries, a highly leveraged balance sheet due to itsacquisitionof the rare disease specialist Shire, and a lack of a franchise-level medication all weighed on its shares during this period. Takeda's shares, in fact, have lost almost a third of their value in just the past three years. However, the company's stock now appears primed for a major reversal for three key reasons.First off, Takeda's Wave 1 clinical pipeline has started to generate some truly high-value commercial products recently. Late last year, for instance, the company scored two important U.S. regulatory approvals for the post-transplant cytomegalovirus infection drug Livtencity and the niche lung cancer medication Exkivity. Takeda believes these two drugs will help drive respectable levels of top-line growth all the way out to fiscal year 2030 and keep its ongoing deleveraging process on track.Second, Takeda's stock is presently trading at 1.5 times fiscal year 2022 projected sales. That's easily one of the lower price-to-sales ratios in the major drug manufacturing space right now. Takeda, in effect, is a bona fide value stock. This ought to benefit the drugmaker's share price in the current value-oriented market.Third, Takeda pays out a sky-high annualized dividend yield of 5.6% right now. The company's stellar yield is also well-funded, evinced by its fairly low payout ratio of 59.4%.All told, Takeda's stock ought to shine as investors rotate into pure-play value stocks and away from riskier growth equities.Viatris: Stability and a top dividend yieldViatris is a generic and biosimilar drug company. Since itsformationa little over a year ago, the company's shares have fallen by over 10.4%. Viatris' stock has so farfailed to exciteinvestors due to itsdebt-laden balance sheet, lack of clear-cut growth products, and rather modest long-term outlook. The company, after all, isn't expecting sustainable top-line growth until 2024.Despite these headwinds, however, Viatris stock should appeal to investors with an eye toward value. The long and short of it is that Viatris' stock is among the absolute cheapest within the realm of dividend-paying pharma stocks right now. Underscoring this point, the drugmaker's shares are presently trading at less than one time forward-looking sales. What's more, Viatris currently offers shareholders an above-average yield -- relative to its peer group -- of 3.29% on an annualized basis.So while Viatris stock isn't going to make shareholders rich anytime soon, this pharma stock does come across as a highly safe investing vehicle, thanks to its bargain bin valuation and attractive dividend yield. And Viatris' top-notch margin of safety should prove to be a winning feature in this risk-averse market.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9093632585,"gmtCreate":1643604578646,"gmtModify":1676533835487,"author":{"id":"4101346711317940","authorId":"4101346711317940","name":"John22","avatar":"https://static.itradeup.com/news/078cdabfb41b19f9945efba2d0f7f43c","vip":1,"hat":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","crmLevel":2,"crmLevelSwitch":0,"idStr":"4101346711317940","authorIdStr":"4101346711317940"},"htmlText":"True","listText":"True","text":"True","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093632585","repostId":1191140677,"repostType":4,"repost":{"id":"1191140677","kind":"news","pubTimestamp":1643509277,"share":"https://ttm.financial/m/news/1191140677?lang=&edition=fundamental","pubTime":"2022-01-30 10:21","market":"us","language":"en","title":"2 Dirt-Cheap Value Stocks to Buy Now","url":"https://stock-news.laohu8.com/highlight/detail?id=1191140677","media":"Motley Fool","summary":"Growth stocks, on balance, have dramatically outperformed value stocks since the last major financia","content":"<html><head></head><body><p>Growth stocks, on balance, have dramatically outperformed value stocks since the last major financial crisis. Historically low federal fund rates (the rate at which banks lend to one another), combined with enormous levels of fiscal stimulus by the U.S. government, were the main drivers behind this unprecedented 14-year-long bull run in growth stocks.</p><p>But with the Federal Reserve poised to roll out a series of interest rate hikes this year, value stocks are probably going to outperform growth stocks for the foreseeable future. In fact, value stocks have already started trouncing growth stocks, in terms of their total return on capital, since the beginning of the fourth quarter of 2021.</p><p>With this powerful trend reversal in mind, investors may want to load up on high-quality value stocks during the opening weeks of 2022. Which value plays are the best buys right now? The dividend-paying pharmaceutical stocks <a href=\"https://laohu8.com/S/TAK\"><b>Takeda Pharmaceutical</b></a> and <a href=\"https://laohu8.com/S/VTRS\"><b>Viatris</b></a> are both currently trading at dirt-cheap valuations. Here&#39;s why investors may want to add these two drugmakers to their portfolios soon.</p><p><a href=\"https://laohu8.com/S/TAK\"><b>Takeda Pharmaceutical</b></a>: An incredibly cheap high-yield dividend stock</p><p>Japanese pharma giant Takeda was one of the few major drug manufacturers to lose ground during the 14-year-long bull market. Various clinical setbacks, upcoming patent expiries, a highly leveraged balance sheet due to itsacquisitionof the rare disease specialist Shire, and a lack of a franchise-level medication all weighed on its shares during this period. Takeda&#39;s shares, in fact, have lost almost a third of their value in just the past three years. However, the company&#39;s stock now appears primed for a major reversal for three key reasons.</p><p>First off, Takeda&#39;s Wave 1 clinical pipeline has started to generate some truly high-value commercial products recently. Late last year, for instance, the company scored two important U.S. regulatory approvals for the post-transplant cytomegalovirus infection drug Livtencity and the niche lung cancer medication Exkivity. Takeda believes these two drugs will help drive respectable levels of top-line growth all the way out to fiscal year 2030 and keep its ongoing deleveraging process on track.</p><p>Second, Takeda&#39;s stock is presently trading at 1.5 times fiscal year 2022 projected sales. That&#39;s easily one of the lower price-to-sales ratios in the major drug manufacturing space right now. Takeda, in effect, is a bona fide value stock. This ought to benefit the drugmaker&#39;s share price in the current value-oriented market.</p><p>Third, Takeda pays out a sky-high annualized dividend yield of 5.6% right now. The company&#39;s stellar yield is also well-funded, evinced by its fairly low payout ratio of 59.4%.</p><p>All told, Takeda&#39;s stock ought to shine as investors rotate into pure-play value stocks and away from riskier growth equities.</p><p><a href=\"https://laohu8.com/S/VTRS\"><b>Viatris</b></a>: Stability and a top dividend yield</p><p>Viatris is a generic and biosimilar drug company. Since itsformationa little over a year ago, the company&#39;s shares have fallen by over 10.4%. Viatris&#39; stock has so farfailed to exciteinvestors due to itsdebt-laden balance sheet, lack of clear-cut growth products, and rather modest long-term outlook. The company, after all, isn&#39;t expecting sustainable top-line growth until 2024.</p><p>Despite these headwinds, however, Viatris stock should appeal to investors with an eye toward value. The long and short of it is that Viatris&#39; stock is among the absolute cheapest within the realm of dividend-paying pharma stocks right now. Underscoring this point, the drugmaker&#39;s shares are presently trading at less than one time forward-looking sales. What&#39;s more, Viatris currently offers shareholders an above-average yield -- relative to its peer group -- of 3.29% on an annualized basis.</p><p>So while Viatris stock isn&#39;t going to make shareholders rich anytime soon, this pharma stock does come across as a highly safe investing vehicle, thanks to its bargain bin valuation and attractive dividend yield. And Viatris&#39; top-notch margin of safety should prove to be a winning feature in this risk-averse market.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Dirt-Cheap Value Stocks to Buy Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Dirt-Cheap Value Stocks to Buy Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-30 10:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/29/2-dirt-cheap-value-stocks-to-buy-now/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Growth stocks, on balance, have dramatically outperformed value stocks since the last major financial crisis. Historically low federal fund rates (the rate at which banks lend to one another), ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/29/2-dirt-cheap-value-stocks-to-buy-now/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VTRS":"Viatris Inc.","TAK":"武田制药"},"source_url":"https://www.fool.com/investing/2022/01/29/2-dirt-cheap-value-stocks-to-buy-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1191140677","content_text":"Growth stocks, on balance, have dramatically outperformed value stocks since the last major financial crisis. Historically low federal fund rates (the rate at which banks lend to one another), combined with enormous levels of fiscal stimulus by the U.S. government, were the main drivers behind this unprecedented 14-year-long bull run in growth stocks.But with the Federal Reserve poised to roll out a series of interest rate hikes this year, value stocks are probably going to outperform growth stocks for the foreseeable future. In fact, value stocks have already started trouncing growth stocks, in terms of their total return on capital, since the beginning of the fourth quarter of 2021.With this powerful trend reversal in mind, investors may want to load up on high-quality value stocks during the opening weeks of 2022. Which value plays are the best buys right now? The dividend-paying pharmaceutical stocks Takeda Pharmaceutical and Viatris are both currently trading at dirt-cheap valuations. Here's why investors may want to add these two drugmakers to their portfolios soon.Takeda Pharmaceutical: An incredibly cheap high-yield dividend stockJapanese pharma giant Takeda was one of the few major drug manufacturers to lose ground during the 14-year-long bull market. Various clinical setbacks, upcoming patent expiries, a highly leveraged balance sheet due to itsacquisitionof the rare disease specialist Shire, and a lack of a franchise-level medication all weighed on its shares during this period. Takeda's shares, in fact, have lost almost a third of their value in just the past three years. However, the company's stock now appears primed for a major reversal for three key reasons.First off, Takeda's Wave 1 clinical pipeline has started to generate some truly high-value commercial products recently. Late last year, for instance, the company scored two important U.S. regulatory approvals for the post-transplant cytomegalovirus infection drug Livtencity and the niche lung cancer medication Exkivity. Takeda believes these two drugs will help drive respectable levels of top-line growth all the way out to fiscal year 2030 and keep its ongoing deleveraging process on track.Second, Takeda's stock is presently trading at 1.5 times fiscal year 2022 projected sales. That's easily one of the lower price-to-sales ratios in the major drug manufacturing space right now. Takeda, in effect, is a bona fide value stock. This ought to benefit the drugmaker's share price in the current value-oriented market.Third, Takeda pays out a sky-high annualized dividend yield of 5.6% right now. The company's stellar yield is also well-funded, evinced by its fairly low payout ratio of 59.4%.All told, Takeda's stock ought to shine as investors rotate into pure-play value stocks and away from riskier growth equities.Viatris: Stability and a top dividend yieldViatris is a generic and biosimilar drug company. Since itsformationa little over a year ago, the company's shares have fallen by over 10.4%. Viatris' stock has so farfailed to exciteinvestors due to itsdebt-laden balance sheet, lack of clear-cut growth products, and rather modest long-term outlook. The company, after all, isn't expecting sustainable top-line growth until 2024.Despite these headwinds, however, Viatris stock should appeal to investors with an eye toward value. The long and short of it is that Viatris' stock is among the absolute cheapest within the realm of dividend-paying pharma stocks right now. Underscoring this point, the drugmaker's shares are presently trading at less than one time forward-looking sales. What's more, Viatris currently offers shareholders an above-average yield -- relative to its peer group -- of 3.29% on an annualized basis.So while Viatris stock isn't going to make shareholders rich anytime soon, this pharma stock does come across as a highly safe investing vehicle, thanks to its bargain bin valuation and attractive dividend yield. And Viatris' top-notch margin of safety should prove to be a winning feature in this risk-averse market.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9093691846,"gmtCreate":1643601841148,"gmtModify":1676533835248,"author":{"id":"3582015516749888","authorId":"3582015516749888","name":"HH浩","avatar":"https://static.tigerbbs.com/2639351c97027c6f71c4d9729ef216d8","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3582015516749888","authorIdStr":"3582015516749888"},"htmlText":"Cheapness based on dividend alone is not asound strategy as dividend come from the profit and sustainability of profit is most important to gauge whether it is a valued buy or not.&nbsp;","listText":"Cheapness based on dividend alone is not asound strategy as dividend come from the profit and sustainability of profit is most important to gauge whether it is a valued buy or not.&nbsp;","text":"Cheapness based on dividend alone is not asound strategy as dividend come from the profit and sustainability of profit is most important to gauge whether it is a valued buy or not.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093691846","repostId":1191140677,"repostType":4,"repost":{"id":"1191140677","kind":"news","pubTimestamp":1643509277,"share":"https://ttm.financial/m/news/1191140677?lang=&edition=fundamental","pubTime":"2022-01-30 10:21","market":"us","language":"en","title":"2 Dirt-Cheap Value Stocks to Buy Now","url":"https://stock-news.laohu8.com/highlight/detail?id=1191140677","media":"Motley Fool","summary":"Growth stocks, on balance, have dramatically outperformed value stocks since the last major financia","content":"<html><head></head><body><p>Growth stocks, on balance, have dramatically outperformed value stocks since the last major financial crisis. Historically low federal fund rates (the rate at which banks lend to one another), combined with enormous levels of fiscal stimulus by the U.S. government, were the main drivers behind this unprecedented 14-year-long bull run in growth stocks.</p><p>But with the Federal Reserve poised to roll out a series of interest rate hikes this year, value stocks are probably going to outperform growth stocks for the foreseeable future. In fact, value stocks have already started trouncing growth stocks, in terms of their total return on capital, since the beginning of the fourth quarter of 2021.</p><p>With this powerful trend reversal in mind, investors may want to load up on high-quality value stocks during the opening weeks of 2022. Which value plays are the best buys right now? The dividend-paying pharmaceutical stocks <a href=\"https://laohu8.com/S/TAK\"><b>Takeda Pharmaceutical</b></a> and <a href=\"https://laohu8.com/S/VTRS\"><b>Viatris</b></a> are both currently trading at dirt-cheap valuations. Here&#39;s why investors may want to add these two drugmakers to their portfolios soon.</p><p><a href=\"https://laohu8.com/S/TAK\"><b>Takeda Pharmaceutical</b></a>: An incredibly cheap high-yield dividend stock</p><p>Japanese pharma giant Takeda was one of the few major drug manufacturers to lose ground during the 14-year-long bull market. Various clinical setbacks, upcoming patent expiries, a highly leveraged balance sheet due to itsacquisitionof the rare disease specialist Shire, and a lack of a franchise-level medication all weighed on its shares during this period. Takeda&#39;s shares, in fact, have lost almost a third of their value in just the past three years. However, the company&#39;s stock now appears primed for a major reversal for three key reasons.</p><p>First off, Takeda&#39;s Wave 1 clinical pipeline has started to generate some truly high-value commercial products recently. Late last year, for instance, the company scored two important U.S. regulatory approvals for the post-transplant cytomegalovirus infection drug Livtencity and the niche lung cancer medication Exkivity. Takeda believes these two drugs will help drive respectable levels of top-line growth all the way out to fiscal year 2030 and keep its ongoing deleveraging process on track.</p><p>Second, Takeda&#39;s stock is presently trading at 1.5 times fiscal year 2022 projected sales. That&#39;s easily one of the lower price-to-sales ratios in the major drug manufacturing space right now. Takeda, in effect, is a bona fide value stock. This ought to benefit the drugmaker&#39;s share price in the current value-oriented market.</p><p>Third, Takeda pays out a sky-high annualized dividend yield of 5.6% right now. The company&#39;s stellar yield is also well-funded, evinced by its fairly low payout ratio of 59.4%.</p><p>All told, Takeda&#39;s stock ought to shine as investors rotate into pure-play value stocks and away from riskier growth equities.</p><p><a href=\"https://laohu8.com/S/VTRS\"><b>Viatris</b></a>: Stability and a top dividend yield</p><p>Viatris is a generic and biosimilar drug company. Since itsformationa little over a year ago, the company&#39;s shares have fallen by over 10.4%. Viatris&#39; stock has so farfailed to exciteinvestors due to itsdebt-laden balance sheet, lack of clear-cut growth products, and rather modest long-term outlook. The company, after all, isn&#39;t expecting sustainable top-line growth until 2024.</p><p>Despite these headwinds, however, Viatris stock should appeal to investors with an eye toward value. The long and short of it is that Viatris&#39; stock is among the absolute cheapest within the realm of dividend-paying pharma stocks right now. Underscoring this point, the drugmaker&#39;s shares are presently trading at less than one time forward-looking sales. What&#39;s more, Viatris currently offers shareholders an above-average yield -- relative to its peer group -- of 3.29% on an annualized basis.</p><p>So while Viatris stock isn&#39;t going to make shareholders rich anytime soon, this pharma stock does come across as a highly safe investing vehicle, thanks to its bargain bin valuation and attractive dividend yield. And Viatris&#39; top-notch margin of safety should prove to be a winning feature in this risk-averse market.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Dirt-Cheap Value Stocks to Buy Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Dirt-Cheap Value Stocks to Buy Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-30 10:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/29/2-dirt-cheap-value-stocks-to-buy-now/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Growth stocks, on balance, have dramatically outperformed value stocks since the last major financial crisis. Historically low federal fund rates (the rate at which banks lend to one another), ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/29/2-dirt-cheap-value-stocks-to-buy-now/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VTRS":"Viatris Inc.","TAK":"武田制药"},"source_url":"https://www.fool.com/investing/2022/01/29/2-dirt-cheap-value-stocks-to-buy-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1191140677","content_text":"Growth stocks, on balance, have dramatically outperformed value stocks since the last major financial crisis. Historically low federal fund rates (the rate at which banks lend to one another), combined with enormous levels of fiscal stimulus by the U.S. government, were the main drivers behind this unprecedented 14-year-long bull run in growth stocks.But with the Federal Reserve poised to roll out a series of interest rate hikes this year, value stocks are probably going to outperform growth stocks for the foreseeable future. In fact, value stocks have already started trouncing growth stocks, in terms of their total return on capital, since the beginning of the fourth quarter of 2021.With this powerful trend reversal in mind, investors may want to load up on high-quality value stocks during the opening weeks of 2022. Which value plays are the best buys right now? The dividend-paying pharmaceutical stocks Takeda Pharmaceutical and Viatris are both currently trading at dirt-cheap valuations. Here's why investors may want to add these two drugmakers to their portfolios soon.Takeda Pharmaceutical: An incredibly cheap high-yield dividend stockJapanese pharma giant Takeda was one of the few major drug manufacturers to lose ground during the 14-year-long bull market. Various clinical setbacks, upcoming patent expiries, a highly leveraged balance sheet due to itsacquisitionof the rare disease specialist Shire, and a lack of a franchise-level medication all weighed on its shares during this period. Takeda's shares, in fact, have lost almost a third of their value in just the past three years. However, the company's stock now appears primed for a major reversal for three key reasons.First off, Takeda's Wave 1 clinical pipeline has started to generate some truly high-value commercial products recently. Late last year, for instance, the company scored two important U.S. regulatory approvals for the post-transplant cytomegalovirus infection drug Livtencity and the niche lung cancer medication Exkivity. Takeda believes these two drugs will help drive respectable levels of top-line growth all the way out to fiscal year 2030 and keep its ongoing deleveraging process on track.Second, Takeda's stock is presently trading at 1.5 times fiscal year 2022 projected sales. That's easily one of the lower price-to-sales ratios in the major drug manufacturing space right now. Takeda, in effect, is a bona fide value stock. This ought to benefit the drugmaker's share price in the current value-oriented market.Third, Takeda pays out a sky-high annualized dividend yield of 5.6% right now. The company's stellar yield is also well-funded, evinced by its fairly low payout ratio of 59.4%.All told, Takeda's stock ought to shine as investors rotate into pure-play value stocks and away from riskier growth equities.Viatris: Stability and a top dividend yieldViatris is a generic and biosimilar drug company. Since itsformationa little over a year ago, the company's shares have fallen by over 10.4%. Viatris' stock has so farfailed to exciteinvestors due to itsdebt-laden balance sheet, lack of clear-cut growth products, and rather modest long-term outlook. The company, after all, isn't expecting sustainable top-line growth until 2024.Despite these headwinds, however, Viatris stock should appeal to investors with an eye toward value. The long and short of it is that Viatris' stock is among the absolute cheapest within the realm of dividend-paying pharma stocks right now. Underscoring this point, the drugmaker's shares are presently trading at less than one time forward-looking sales. What's more, Viatris currently offers shareholders an above-average yield -- relative to its peer group -- of 3.29% on an annualized basis.So while Viatris stock isn't going to make shareholders rich anytime soon, this pharma stock does come across as a highly safe investing vehicle, thanks to its bargain bin valuation and attractive dividend yield. And Viatris' top-notch margin of safety should prove to be a winning feature in this risk-averse market.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9093699879,"gmtCreate":1643601471287,"gmtModify":1676533835180,"author":{"id":"4101868132463050","authorId":"4101868132463050","name":"Gneiss","avatar":"https://static.tigerbbs.com/04e6942e7cce10823f5ef0af66f4c932","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4101868132463050","authorIdStr":"4101868132463050"},"htmlText":"Thank you for this","listText":"Thank you for this","text":"Thank you for this","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093699879","repostId":1191140677,"repostType":4,"repost":{"id":"1191140677","kind":"news","pubTimestamp":1643509277,"share":"https://ttm.financial/m/news/1191140677?lang=&edition=fundamental","pubTime":"2022-01-30 10:21","market":"us","language":"en","title":"2 Dirt-Cheap Value Stocks to Buy Now","url":"https://stock-news.laohu8.com/highlight/detail?id=1191140677","media":"Motley Fool","summary":"Growth stocks, on balance, have dramatically outperformed value stocks since the last major financia","content":"<html><head></head><body><p>Growth stocks, on balance, have dramatically outperformed value stocks since the last major financial crisis. Historically low federal fund rates (the rate at which banks lend to one another), combined with enormous levels of fiscal stimulus by the U.S. government, were the main drivers behind this unprecedented 14-year-long bull run in growth stocks.</p><p>But with the Federal Reserve poised to roll out a series of interest rate hikes this year, value stocks are probably going to outperform growth stocks for the foreseeable future. In fact, value stocks have already started trouncing growth stocks, in terms of their total return on capital, since the beginning of the fourth quarter of 2021.</p><p>With this powerful trend reversal in mind, investors may want to load up on high-quality value stocks during the opening weeks of 2022. Which value plays are the best buys right now? The dividend-paying pharmaceutical stocks <a href=\"https://laohu8.com/S/TAK\"><b>Takeda Pharmaceutical</b></a> and <a href=\"https://laohu8.com/S/VTRS\"><b>Viatris</b></a> are both currently trading at dirt-cheap valuations. Here&#39;s why investors may want to add these two drugmakers to their portfolios soon.</p><p><a href=\"https://laohu8.com/S/TAK\"><b>Takeda Pharmaceutical</b></a>: An incredibly cheap high-yield dividend stock</p><p>Japanese pharma giant Takeda was one of the few major drug manufacturers to lose ground during the 14-year-long bull market. Various clinical setbacks, upcoming patent expiries, a highly leveraged balance sheet due to itsacquisitionof the rare disease specialist Shire, and a lack of a franchise-level medication all weighed on its shares during this period. Takeda&#39;s shares, in fact, have lost almost a third of their value in just the past three years. However, the company&#39;s stock now appears primed for a major reversal for three key reasons.</p><p>First off, Takeda&#39;s Wave 1 clinical pipeline has started to generate some truly high-value commercial products recently. Late last year, for instance, the company scored two important U.S. regulatory approvals for the post-transplant cytomegalovirus infection drug Livtencity and the niche lung cancer medication Exkivity. Takeda believes these two drugs will help drive respectable levels of top-line growth all the way out to fiscal year 2030 and keep its ongoing deleveraging process on track.</p><p>Second, Takeda&#39;s stock is presently trading at 1.5 times fiscal year 2022 projected sales. That&#39;s easily one of the lower price-to-sales ratios in the major drug manufacturing space right now. Takeda, in effect, is a bona fide value stock. This ought to benefit the drugmaker&#39;s share price in the current value-oriented market.</p><p>Third, Takeda pays out a sky-high annualized dividend yield of 5.6% right now. The company&#39;s stellar yield is also well-funded, evinced by its fairly low payout ratio of 59.4%.</p><p>All told, Takeda&#39;s stock ought to shine as investors rotate into pure-play value stocks and away from riskier growth equities.</p><p><a href=\"https://laohu8.com/S/VTRS\"><b>Viatris</b></a>: Stability and a top dividend yield</p><p>Viatris is a generic and biosimilar drug company. Since itsformationa little over a year ago, the company&#39;s shares have fallen by over 10.4%. Viatris&#39; stock has so farfailed to exciteinvestors due to itsdebt-laden balance sheet, lack of clear-cut growth products, and rather modest long-term outlook. The company, after all, isn&#39;t expecting sustainable top-line growth until 2024.</p><p>Despite these headwinds, however, Viatris stock should appeal to investors with an eye toward value. The long and short of it is that Viatris&#39; stock is among the absolute cheapest within the realm of dividend-paying pharma stocks right now. Underscoring this point, the drugmaker&#39;s shares are presently trading at less than one time forward-looking sales. What&#39;s more, Viatris currently offers shareholders an above-average yield -- relative to its peer group -- of 3.29% on an annualized basis.</p><p>So while Viatris stock isn&#39;t going to make shareholders rich anytime soon, this pharma stock does come across as a highly safe investing vehicle, thanks to its bargain bin valuation and attractive dividend yield. And Viatris&#39; top-notch margin of safety should prove to be a winning feature in this risk-averse market.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Dirt-Cheap Value Stocks to Buy Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Dirt-Cheap Value Stocks to Buy Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-30 10:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/29/2-dirt-cheap-value-stocks-to-buy-now/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Growth stocks, on balance, have dramatically outperformed value stocks since the last major financial crisis. Historically low federal fund rates (the rate at which banks lend to one another), ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/29/2-dirt-cheap-value-stocks-to-buy-now/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VTRS":"Viatris Inc.","TAK":"武田制药"},"source_url":"https://www.fool.com/investing/2022/01/29/2-dirt-cheap-value-stocks-to-buy-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1191140677","content_text":"Growth stocks, on balance, have dramatically outperformed value stocks since the last major financial crisis. Historically low federal fund rates (the rate at which banks lend to one another), combined with enormous levels of fiscal stimulus by the U.S. government, were the main drivers behind this unprecedented 14-year-long bull run in growth stocks.But with the Federal Reserve poised to roll out a series of interest rate hikes this year, value stocks are probably going to outperform growth stocks for the foreseeable future. In fact, value stocks have already started trouncing growth stocks, in terms of their total return on capital, since the beginning of the fourth quarter of 2021.With this powerful trend reversal in mind, investors may want to load up on high-quality value stocks during the opening weeks of 2022. Which value plays are the best buys right now? The dividend-paying pharmaceutical stocks Takeda Pharmaceutical and Viatris are both currently trading at dirt-cheap valuations. Here's why investors may want to add these two drugmakers to their portfolios soon.Takeda Pharmaceutical: An incredibly cheap high-yield dividend stockJapanese pharma giant Takeda was one of the few major drug manufacturers to lose ground during the 14-year-long bull market. Various clinical setbacks, upcoming patent expiries, a highly leveraged balance sheet due to itsacquisitionof the rare disease specialist Shire, and a lack of a franchise-level medication all weighed on its shares during this period. Takeda's shares, in fact, have lost almost a third of their value in just the past three years. However, the company's stock now appears primed for a major reversal for three key reasons.First off, Takeda's Wave 1 clinical pipeline has started to generate some truly high-value commercial products recently. Late last year, for instance, the company scored two important U.S. regulatory approvals for the post-transplant cytomegalovirus infection drug Livtencity and the niche lung cancer medication Exkivity. Takeda believes these two drugs will help drive respectable levels of top-line growth all the way out to fiscal year 2030 and keep its ongoing deleveraging process on track.Second, Takeda's stock is presently trading at 1.5 times fiscal year 2022 projected sales. That's easily one of the lower price-to-sales ratios in the major drug manufacturing space right now. Takeda, in effect, is a bona fide value stock. This ought to benefit the drugmaker's share price in the current value-oriented market.Third, Takeda pays out a sky-high annualized dividend yield of 5.6% right now. The company's stellar yield is also well-funded, evinced by its fairly low payout ratio of 59.4%.All told, Takeda's stock ought to shine as investors rotate into pure-play value stocks and away from riskier growth equities.Viatris: Stability and a top dividend yieldViatris is a generic and biosimilar drug company. Since itsformationa little over a year ago, the company's shares have fallen by over 10.4%. Viatris' stock has so farfailed to exciteinvestors due to itsdebt-laden balance sheet, lack of clear-cut growth products, and rather modest long-term outlook. The company, after all, isn't expecting sustainable top-line growth until 2024.Despite these headwinds, however, Viatris stock should appeal to investors with an eye toward value. The long and short of it is that Viatris' stock is among the absolute cheapest within the realm of dividend-paying pharma stocks right now. Underscoring this point, the drugmaker's shares are presently trading at less than one time forward-looking sales. What's more, Viatris currently offers shareholders an above-average yield -- relative to its peer group -- of 3.29% on an annualized basis.So while Viatris stock isn't going to make shareholders rich anytime soon, this pharma stock does come across as a highly safe investing vehicle, thanks to its bargain bin valuation and attractive dividend yield. And Viatris' top-notch margin of safety should prove to be a winning feature in this risk-averse market.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9093609399,"gmtCreate":1643599405133,"gmtModify":1676533834941,"author":{"id":"4092970777728640","authorId":"4092970777728640","name":"SCLIEW","avatar":"https://static.tigerbbs.com/5da553e4d3d35db75d1caae023ca8a03","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4092970777728640","authorIdStr":"4092970777728640"},"htmlText":"666","listText":"666","text":"666","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093609399","repostId":1191140677,"repostType":4,"repost":{"id":"1191140677","kind":"news","pubTimestamp":1643509277,"share":"https://ttm.financial/m/news/1191140677?lang=&edition=fundamental","pubTime":"2022-01-30 10:21","market":"us","language":"en","title":"2 Dirt-Cheap Value Stocks to Buy Now","url":"https://stock-news.laohu8.com/highlight/detail?id=1191140677","media":"Motley Fool","summary":"Growth stocks, on balance, have dramatically outperformed value stocks since the last major financia","content":"<html><head></head><body><p>Growth stocks, on balance, have dramatically outperformed value stocks since the last major financial crisis. Historically low federal fund rates (the rate at which banks lend to one another), combined with enormous levels of fiscal stimulus by the U.S. government, were the main drivers behind this unprecedented 14-year-long bull run in growth stocks.</p><p>But with the Federal Reserve poised to roll out a series of interest rate hikes this year, value stocks are probably going to outperform growth stocks for the foreseeable future. In fact, value stocks have already started trouncing growth stocks, in terms of their total return on capital, since the beginning of the fourth quarter of 2021.</p><p>With this powerful trend reversal in mind, investors may want to load up on high-quality value stocks during the opening weeks of 2022. Which value plays are the best buys right now? The dividend-paying pharmaceutical stocks <a href=\"https://laohu8.com/S/TAK\"><b>Takeda Pharmaceutical</b></a> and <a href=\"https://laohu8.com/S/VTRS\"><b>Viatris</b></a> are both currently trading at dirt-cheap valuations. Here&#39;s why investors may want to add these two drugmakers to their portfolios soon.</p><p><a href=\"https://laohu8.com/S/TAK\"><b>Takeda Pharmaceutical</b></a>: An incredibly cheap high-yield dividend stock</p><p>Japanese pharma giant Takeda was one of the few major drug manufacturers to lose ground during the 14-year-long bull market. Various clinical setbacks, upcoming patent expiries, a highly leveraged balance sheet due to itsacquisitionof the rare disease specialist Shire, and a lack of a franchise-level medication all weighed on its shares during this period. Takeda&#39;s shares, in fact, have lost almost a third of their value in just the past three years. However, the company&#39;s stock now appears primed for a major reversal for three key reasons.</p><p>First off, Takeda&#39;s Wave 1 clinical pipeline has started to generate some truly high-value commercial products recently. Late last year, for instance, the company scored two important U.S. regulatory approvals for the post-transplant cytomegalovirus infection drug Livtencity and the niche lung cancer medication Exkivity. Takeda believes these two drugs will help drive respectable levels of top-line growth all the way out to fiscal year 2030 and keep its ongoing deleveraging process on track.</p><p>Second, Takeda&#39;s stock is presently trading at 1.5 times fiscal year 2022 projected sales. That&#39;s easily one of the lower price-to-sales ratios in the major drug manufacturing space right now. Takeda, in effect, is a bona fide value stock. This ought to benefit the drugmaker&#39;s share price in the current value-oriented market.</p><p>Third, Takeda pays out a sky-high annualized dividend yield of 5.6% right now. The company&#39;s stellar yield is also well-funded, evinced by its fairly low payout ratio of 59.4%.</p><p>All told, Takeda&#39;s stock ought to shine as investors rotate into pure-play value stocks and away from riskier growth equities.</p><p><a href=\"https://laohu8.com/S/VTRS\"><b>Viatris</b></a>: Stability and a top dividend yield</p><p>Viatris is a generic and biosimilar drug company. Since itsformationa little over a year ago, the company&#39;s shares have fallen by over 10.4%. Viatris&#39; stock has so farfailed to exciteinvestors due to itsdebt-laden balance sheet, lack of clear-cut growth products, and rather modest long-term outlook. The company, after all, isn&#39;t expecting sustainable top-line growth until 2024.</p><p>Despite these headwinds, however, Viatris stock should appeal to investors with an eye toward value. The long and short of it is that Viatris&#39; stock is among the absolute cheapest within the realm of dividend-paying pharma stocks right now. Underscoring this point, the drugmaker&#39;s shares are presently trading at less than one time forward-looking sales. What&#39;s more, Viatris currently offers shareholders an above-average yield -- relative to its peer group -- of 3.29% on an annualized basis.</p><p>So while Viatris stock isn&#39;t going to make shareholders rich anytime soon, this pharma stock does come across as a highly safe investing vehicle, thanks to its bargain bin valuation and attractive dividend yield. And Viatris&#39; top-notch margin of safety should prove to be a winning feature in this risk-averse market.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Dirt-Cheap Value Stocks to Buy Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Dirt-Cheap Value Stocks to Buy Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-30 10:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/29/2-dirt-cheap-value-stocks-to-buy-now/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Growth stocks, on balance, have dramatically outperformed value stocks since the last major financial crisis. Historically low federal fund rates (the rate at which banks lend to one another), ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/29/2-dirt-cheap-value-stocks-to-buy-now/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VTRS":"Viatris Inc.","TAK":"武田制药"},"source_url":"https://www.fool.com/investing/2022/01/29/2-dirt-cheap-value-stocks-to-buy-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1191140677","content_text":"Growth stocks, on balance, have dramatically outperformed value stocks since the last major financial crisis. Historically low federal fund rates (the rate at which banks lend to one another), combined with enormous levels of fiscal stimulus by the U.S. government, were the main drivers behind this unprecedented 14-year-long bull run in growth stocks.But with the Federal Reserve poised to roll out a series of interest rate hikes this year, value stocks are probably going to outperform growth stocks for the foreseeable future. In fact, value stocks have already started trouncing growth stocks, in terms of their total return on capital, since the beginning of the fourth quarter of 2021.With this powerful trend reversal in mind, investors may want to load up on high-quality value stocks during the opening weeks of 2022. Which value plays are the best buys right now? The dividend-paying pharmaceutical stocks Takeda Pharmaceutical and Viatris are both currently trading at dirt-cheap valuations. Here's why investors may want to add these two drugmakers to their portfolios soon.Takeda Pharmaceutical: An incredibly cheap high-yield dividend stockJapanese pharma giant Takeda was one of the few major drug manufacturers to lose ground during the 14-year-long bull market. Various clinical setbacks, upcoming patent expiries, a highly leveraged balance sheet due to itsacquisitionof the rare disease specialist Shire, and a lack of a franchise-level medication all weighed on its shares during this period. Takeda's shares, in fact, have lost almost a third of their value in just the past three years. However, the company's stock now appears primed for a major reversal for three key reasons.First off, Takeda's Wave 1 clinical pipeline has started to generate some truly high-value commercial products recently. Late last year, for instance, the company scored two important U.S. regulatory approvals for the post-transplant cytomegalovirus infection drug Livtencity and the niche lung cancer medication Exkivity. Takeda believes these two drugs will help drive respectable levels of top-line growth all the way out to fiscal year 2030 and keep its ongoing deleveraging process on track.Second, Takeda's stock is presently trading at 1.5 times fiscal year 2022 projected sales. That's easily one of the lower price-to-sales ratios in the major drug manufacturing space right now. Takeda, in effect, is a bona fide value stock. This ought to benefit the drugmaker's share price in the current value-oriented market.Third, Takeda pays out a sky-high annualized dividend yield of 5.6% right now. The company's stellar yield is also well-funded, evinced by its fairly low payout ratio of 59.4%.All told, Takeda's stock ought to shine as investors rotate into pure-play value stocks and away from riskier growth equities.Viatris: Stability and a top dividend yieldViatris is a generic and biosimilar drug company. Since itsformationa little over a year ago, the company's shares have fallen by over 10.4%. Viatris' stock has so farfailed to exciteinvestors due to itsdebt-laden balance sheet, lack of clear-cut growth products, and rather modest long-term outlook. The company, after all, isn't expecting sustainable top-line growth until 2024.Despite these headwinds, however, Viatris stock should appeal to investors with an eye toward value. The long and short of it is that Viatris' stock is among the absolute cheapest within the realm of dividend-paying pharma stocks right now. Underscoring this point, the drugmaker's shares are presently trading at less than one time forward-looking sales. What's more, Viatris currently offers shareholders an above-average yield -- relative to its peer group -- of 3.29% on an annualized basis.So while Viatris stock isn't going to make shareholders rich anytime soon, this pharma stock does come across as a highly safe investing vehicle, thanks to its bargain bin valuation and attractive dividend yield. And Viatris' top-notch margin of safety should prove to be a winning feature in this risk-averse market.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9093847396,"gmtCreate":1643597031464,"gmtModify":1676533834581,"author":{"id":"3581575705235184","authorId":"3581575705235184","name":"Huat Huat Ah","avatar":"https://static.tigerbbs.com/3974791aaf5f68ecdd8c0ed6549fa6e7","vip":1,"hat":"https://static.tigerbbs.com/a3dee1aa3a3a3c1814833a4d3f8a5669","crmLevel":3,"crmLevelSwitch":1,"idStr":"3581575705235184","authorIdStr":"3581575705235184"},"htmlText":"Huat huat all","listText":"Huat huat all","text":"Huat huat all","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093847396","repostId":1191140677,"repostType":4,"repost":{"id":"1191140677","kind":"news","pubTimestamp":1643509277,"share":"https://ttm.financial/m/news/1191140677?lang=&edition=fundamental","pubTime":"2022-01-30 10:21","market":"us","language":"en","title":"2 Dirt-Cheap Value Stocks to Buy Now","url":"https://stock-news.laohu8.com/highlight/detail?id=1191140677","media":"Motley Fool","summary":"Growth stocks, on balance, have dramatically outperformed value stocks since the last major financia","content":"<html><head></head><body><p>Growth stocks, on balance, have dramatically outperformed value stocks since the last major financial crisis. Historically low federal fund rates (the rate at which banks lend to one another), combined with enormous levels of fiscal stimulus by the U.S. government, were the main drivers behind this unprecedented 14-year-long bull run in growth stocks.</p><p>But with the Federal Reserve poised to roll out a series of interest rate hikes this year, value stocks are probably going to outperform growth stocks for the foreseeable future. In fact, value stocks have already started trouncing growth stocks, in terms of their total return on capital, since the beginning of the fourth quarter of 2021.</p><p>With this powerful trend reversal in mind, investors may want to load up on high-quality value stocks during the opening weeks of 2022. Which value plays are the best buys right now? The dividend-paying pharmaceutical stocks <a href=\"https://laohu8.com/S/TAK\"><b>Takeda Pharmaceutical</b></a> and <a href=\"https://laohu8.com/S/VTRS\"><b>Viatris</b></a> are both currently trading at dirt-cheap valuations. Here&#39;s why investors may want to add these two drugmakers to their portfolios soon.</p><p><a href=\"https://laohu8.com/S/TAK\"><b>Takeda Pharmaceutical</b></a>: An incredibly cheap high-yield dividend stock</p><p>Japanese pharma giant Takeda was one of the few major drug manufacturers to lose ground during the 14-year-long bull market. Various clinical setbacks, upcoming patent expiries, a highly leveraged balance sheet due to itsacquisitionof the rare disease specialist Shire, and a lack of a franchise-level medication all weighed on its shares during this period. Takeda&#39;s shares, in fact, have lost almost a third of their value in just the past three years. However, the company&#39;s stock now appears primed for a major reversal for three key reasons.</p><p>First off, Takeda&#39;s Wave 1 clinical pipeline has started to generate some truly high-value commercial products recently. Late last year, for instance, the company scored two important U.S. regulatory approvals for the post-transplant cytomegalovirus infection drug Livtencity and the niche lung cancer medication Exkivity. Takeda believes these two drugs will help drive respectable levels of top-line growth all the way out to fiscal year 2030 and keep its ongoing deleveraging process on track.</p><p>Second, Takeda&#39;s stock is presently trading at 1.5 times fiscal year 2022 projected sales. That&#39;s easily one of the lower price-to-sales ratios in the major drug manufacturing space right now. Takeda, in effect, is a bona fide value stock. This ought to benefit the drugmaker&#39;s share price in the current value-oriented market.</p><p>Third, Takeda pays out a sky-high annualized dividend yield of 5.6% right now. The company&#39;s stellar yield is also well-funded, evinced by its fairly low payout ratio of 59.4%.</p><p>All told, Takeda&#39;s stock ought to shine as investors rotate into pure-play value stocks and away from riskier growth equities.</p><p><a href=\"https://laohu8.com/S/VTRS\"><b>Viatris</b></a>: Stability and a top dividend yield</p><p>Viatris is a generic and biosimilar drug company. Since itsformationa little over a year ago, the company&#39;s shares have fallen by over 10.4%. Viatris&#39; stock has so farfailed to exciteinvestors due to itsdebt-laden balance sheet, lack of clear-cut growth products, and rather modest long-term outlook. The company, after all, isn&#39;t expecting sustainable top-line growth until 2024.</p><p>Despite these headwinds, however, Viatris stock should appeal to investors with an eye toward value. The long and short of it is that Viatris&#39; stock is among the absolute cheapest within the realm of dividend-paying pharma stocks right now. Underscoring this point, the drugmaker&#39;s shares are presently trading at less than one time forward-looking sales. What&#39;s more, Viatris currently offers shareholders an above-average yield -- relative to its peer group -- of 3.29% on an annualized basis.</p><p>So while Viatris stock isn&#39;t going to make shareholders rich anytime soon, this pharma stock does come across as a highly safe investing vehicle, thanks to its bargain bin valuation and attractive dividend yield. And Viatris&#39; top-notch margin of safety should prove to be a winning feature in this risk-averse market.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Dirt-Cheap Value Stocks to Buy Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Dirt-Cheap Value Stocks to Buy Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-30 10:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/29/2-dirt-cheap-value-stocks-to-buy-now/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Growth stocks, on balance, have dramatically outperformed value stocks since the last major financial crisis. Historically low federal fund rates (the rate at which banks lend to one another), ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/29/2-dirt-cheap-value-stocks-to-buy-now/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VTRS":"Viatris Inc.","TAK":"武田制药"},"source_url":"https://www.fool.com/investing/2022/01/29/2-dirt-cheap-value-stocks-to-buy-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1191140677","content_text":"Growth stocks, on balance, have dramatically outperformed value stocks since the last major financial crisis. Historically low federal fund rates (the rate at which banks lend to one another), combined with enormous levels of fiscal stimulus by the U.S. government, were the main drivers behind this unprecedented 14-year-long bull run in growth stocks.But with the Federal Reserve poised to roll out a series of interest rate hikes this year, value stocks are probably going to outperform growth stocks for the foreseeable future. In fact, value stocks have already started trouncing growth stocks, in terms of their total return on capital, since the beginning of the fourth quarter of 2021.With this powerful trend reversal in mind, investors may want to load up on high-quality value stocks during the opening weeks of 2022. Which value plays are the best buys right now? The dividend-paying pharmaceutical stocks Takeda Pharmaceutical and Viatris are both currently trading at dirt-cheap valuations. Here's why investors may want to add these two drugmakers to their portfolios soon.Takeda Pharmaceutical: An incredibly cheap high-yield dividend stockJapanese pharma giant Takeda was one of the few major drug manufacturers to lose ground during the 14-year-long bull market. Various clinical setbacks, upcoming patent expiries, a highly leveraged balance sheet due to itsacquisitionof the rare disease specialist Shire, and a lack of a franchise-level medication all weighed on its shares during this period. Takeda's shares, in fact, have lost almost a third of their value in just the past three years. However, the company's stock now appears primed for a major reversal for three key reasons.First off, Takeda's Wave 1 clinical pipeline has started to generate some truly high-value commercial products recently. Late last year, for instance, the company scored two important U.S. regulatory approvals for the post-transplant cytomegalovirus infection drug Livtencity and the niche lung cancer medication Exkivity. Takeda believes these two drugs will help drive respectable levels of top-line growth all the way out to fiscal year 2030 and keep its ongoing deleveraging process on track.Second, Takeda's stock is presently trading at 1.5 times fiscal year 2022 projected sales. That's easily one of the lower price-to-sales ratios in the major drug manufacturing space right now. Takeda, in effect, is a bona fide value stock. This ought to benefit the drugmaker's share price in the current value-oriented market.Third, Takeda pays out a sky-high annualized dividend yield of 5.6% right now. The company's stellar yield is also well-funded, evinced by its fairly low payout ratio of 59.4%.All told, Takeda's stock ought to shine as investors rotate into pure-play value stocks and away from riskier growth equities.Viatris: Stability and a top dividend yieldViatris is a generic and biosimilar drug company. Since itsformationa little over a year ago, the company's shares have fallen by over 10.4%. Viatris' stock has so farfailed to exciteinvestors due to itsdebt-laden balance sheet, lack of clear-cut growth products, and rather modest long-term outlook. The company, after all, isn't expecting sustainable top-line growth until 2024.Despite these headwinds, however, Viatris stock should appeal to investors with an eye toward value. The long and short of it is that Viatris' stock is among the absolute cheapest within the realm of dividend-paying pharma stocks right now. Underscoring this point, the drugmaker's shares are presently trading at less than one time forward-looking sales. What's more, Viatris currently offers shareholders an above-average yield -- relative to its peer group -- of 3.29% on an annualized basis.So while Viatris stock isn't going to make shareholders rich anytime soon, this pharma stock does come across as a highly safe investing vehicle, thanks to its bargain bin valuation and attractive dividend yield. And Viatris' top-notch margin of safety should prove to be a winning feature in this risk-averse market.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9093889376,"gmtCreate":1643589891506,"gmtModify":1676533833400,"author":{"id":"3586490638953193","authorId":"3586490638953193","name":"Jess261","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3586490638953193","authorIdStr":"3586490638953193"},"htmlText":"Okay","listText":"Okay","text":"Okay","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093889376","repostId":1191140677,"repostType":4,"repost":{"id":"1191140677","kind":"news","pubTimestamp":1643509277,"share":"https://ttm.financial/m/news/1191140677?lang=&edition=fundamental","pubTime":"2022-01-30 10:21","market":"us","language":"en","title":"2 Dirt-Cheap Value Stocks to Buy Now","url":"https://stock-news.laohu8.com/highlight/detail?id=1191140677","media":"Motley Fool","summary":"Growth stocks, on balance, have dramatically outperformed value stocks since the last major financia","content":"<html><head></head><body><p>Growth stocks, on balance, have dramatically outperformed value stocks since the last major financial crisis. Historically low federal fund rates (the rate at which banks lend to one another), combined with enormous levels of fiscal stimulus by the U.S. government, were the main drivers behind this unprecedented 14-year-long bull run in growth stocks.</p><p>But with the Federal Reserve poised to roll out a series of interest rate hikes this year, value stocks are probably going to outperform growth stocks for the foreseeable future. In fact, value stocks have already started trouncing growth stocks, in terms of their total return on capital, since the beginning of the fourth quarter of 2021.</p><p>With this powerful trend reversal in mind, investors may want to load up on high-quality value stocks during the opening weeks of 2022. Which value plays are the best buys right now? The dividend-paying pharmaceutical stocks <a href=\"https://laohu8.com/S/TAK\"><b>Takeda Pharmaceutical</b></a> and <a href=\"https://laohu8.com/S/VTRS\"><b>Viatris</b></a> are both currently trading at dirt-cheap valuations. Here&#39;s why investors may want to add these two drugmakers to their portfolios soon.</p><p><a href=\"https://laohu8.com/S/TAK\"><b>Takeda Pharmaceutical</b></a>: An incredibly cheap high-yield dividend stock</p><p>Japanese pharma giant Takeda was one of the few major drug manufacturers to lose ground during the 14-year-long bull market. Various clinical setbacks, upcoming patent expiries, a highly leveraged balance sheet due to itsacquisitionof the rare disease specialist Shire, and a lack of a franchise-level medication all weighed on its shares during this period. Takeda&#39;s shares, in fact, have lost almost a third of their value in just the past three years. However, the company&#39;s stock now appears primed for a major reversal for three key reasons.</p><p>First off, Takeda&#39;s Wave 1 clinical pipeline has started to generate some truly high-value commercial products recently. Late last year, for instance, the company scored two important U.S. regulatory approvals for the post-transplant cytomegalovirus infection drug Livtencity and the niche lung cancer medication Exkivity. Takeda believes these two drugs will help drive respectable levels of top-line growth all the way out to fiscal year 2030 and keep its ongoing deleveraging process on track.</p><p>Second, Takeda&#39;s stock is presently trading at 1.5 times fiscal year 2022 projected sales. That&#39;s easily one of the lower price-to-sales ratios in the major drug manufacturing space right now. Takeda, in effect, is a bona fide value stock. This ought to benefit the drugmaker&#39;s share price in the current value-oriented market.</p><p>Third, Takeda pays out a sky-high annualized dividend yield of 5.6% right now. The company&#39;s stellar yield is also well-funded, evinced by its fairly low payout ratio of 59.4%.</p><p>All told, Takeda&#39;s stock ought to shine as investors rotate into pure-play value stocks and away from riskier growth equities.</p><p><a href=\"https://laohu8.com/S/VTRS\"><b>Viatris</b></a>: Stability and a top dividend yield</p><p>Viatris is a generic and biosimilar drug company. Since itsformationa little over a year ago, the company&#39;s shares have fallen by over 10.4%. Viatris&#39; stock has so farfailed to exciteinvestors due to itsdebt-laden balance sheet, lack of clear-cut growth products, and rather modest long-term outlook. The company, after all, isn&#39;t expecting sustainable top-line growth until 2024.</p><p>Despite these headwinds, however, Viatris stock should appeal to investors with an eye toward value. The long and short of it is that Viatris&#39; stock is among the absolute cheapest within the realm of dividend-paying pharma stocks right now. Underscoring this point, the drugmaker&#39;s shares are presently trading at less than one time forward-looking sales. What&#39;s more, Viatris currently offers shareholders an above-average yield -- relative to its peer group -- of 3.29% on an annualized basis.</p><p>So while Viatris stock isn&#39;t going to make shareholders rich anytime soon, this pharma stock does come across as a highly safe investing vehicle, thanks to its bargain bin valuation and attractive dividend yield. And Viatris&#39; top-notch margin of safety should prove to be a winning feature in this risk-averse market.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Dirt-Cheap Value Stocks to Buy Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Dirt-Cheap Value Stocks to Buy Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-30 10:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/29/2-dirt-cheap-value-stocks-to-buy-now/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Growth stocks, on balance, have dramatically outperformed value stocks since the last major financial crisis. Historically low federal fund rates (the rate at which banks lend to one another), ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/29/2-dirt-cheap-value-stocks-to-buy-now/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VTRS":"Viatris Inc.","TAK":"武田制药"},"source_url":"https://www.fool.com/investing/2022/01/29/2-dirt-cheap-value-stocks-to-buy-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1191140677","content_text":"Growth stocks, on balance, have dramatically outperformed value stocks since the last major financial crisis. Historically low federal fund rates (the rate at which banks lend to one another), combined with enormous levels of fiscal stimulus by the U.S. government, were the main drivers behind this unprecedented 14-year-long bull run in growth stocks.But with the Federal Reserve poised to roll out a series of interest rate hikes this year, value stocks are probably going to outperform growth stocks for the foreseeable future. In fact, value stocks have already started trouncing growth stocks, in terms of their total return on capital, since the beginning of the fourth quarter of 2021.With this powerful trend reversal in mind, investors may want to load up on high-quality value stocks during the opening weeks of 2022. Which value plays are the best buys right now? The dividend-paying pharmaceutical stocks Takeda Pharmaceutical and Viatris are both currently trading at dirt-cheap valuations. Here's why investors may want to add these two drugmakers to their portfolios soon.Takeda Pharmaceutical: An incredibly cheap high-yield dividend stockJapanese pharma giant Takeda was one of the few major drug manufacturers to lose ground during the 14-year-long bull market. Various clinical setbacks, upcoming patent expiries, a highly leveraged balance sheet due to itsacquisitionof the rare disease specialist Shire, and a lack of a franchise-level medication all weighed on its shares during this period. Takeda's shares, in fact, have lost almost a third of their value in just the past three years. However, the company's stock now appears primed for a major reversal for three key reasons.First off, Takeda's Wave 1 clinical pipeline has started to generate some truly high-value commercial products recently. Late last year, for instance, the company scored two important U.S. regulatory approvals for the post-transplant cytomegalovirus infection drug Livtencity and the niche lung cancer medication Exkivity. Takeda believes these two drugs will help drive respectable levels of top-line growth all the way out to fiscal year 2030 and keep its ongoing deleveraging process on track.Second, Takeda's stock is presently trading at 1.5 times fiscal year 2022 projected sales. That's easily one of the lower price-to-sales ratios in the major drug manufacturing space right now. Takeda, in effect, is a bona fide value stock. This ought to benefit the drugmaker's share price in the current value-oriented market.Third, Takeda pays out a sky-high annualized dividend yield of 5.6% right now. The company's stellar yield is also well-funded, evinced by its fairly low payout ratio of 59.4%.All told, Takeda's stock ought to shine as investors rotate into pure-play value stocks and away from riskier growth equities.Viatris: Stability and a top dividend yieldViatris is a generic and biosimilar drug company. Since itsformationa little over a year ago, the company's shares have fallen by over 10.4%. Viatris' stock has so farfailed to exciteinvestors due to itsdebt-laden balance sheet, lack of clear-cut growth products, and rather modest long-term outlook. The company, after all, isn't expecting sustainable top-line growth until 2024.Despite these headwinds, however, Viatris stock should appeal to investors with an eye toward value. The long and short of it is that Viatris' stock is among the absolute cheapest within the realm of dividend-paying pharma stocks right now. Underscoring this point, the drugmaker's shares are presently trading at less than one time forward-looking sales. What's more, Viatris currently offers shareholders an above-average yield -- relative to its peer group -- of 3.29% on an annualized basis.So while Viatris stock isn't going to make shareholders rich anytime soon, this pharma stock does come across as a highly safe investing vehicle, thanks to its bargain bin valuation and attractive dividend yield. And Viatris' top-notch margin of safety should prove to be a winning feature in this risk-averse market.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9093830717,"gmtCreate":1643587425553,"gmtModify":1676533832934,"author":{"id":"4091925166419540","authorId":"4091925166419540","name":"Jazim","avatar":"https://static.tigerbbs.com/85de7ecb80758afc3288fc8bb7e5ef27","vip":1,"crmLevel":6,"crmLevelSwitch":0,"idStr":"4091925166419540","authorIdStr":"4091925166419540"},"htmlText":"Okay","listText":"Okay","text":"Okay","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093830717","repostId":1191140677,"repostType":4,"repost":{"id":"1191140677","kind":"news","pubTimestamp":1643509277,"share":"https://ttm.financial/m/news/1191140677?lang=&edition=fundamental","pubTime":"2022-01-30 10:21","market":"us","language":"en","title":"2 Dirt-Cheap Value Stocks to Buy Now","url":"https://stock-news.laohu8.com/highlight/detail?id=1191140677","media":"Motley Fool","summary":"Growth stocks, on balance, have dramatically outperformed value stocks since the last major financia","content":"<html><head></head><body><p>Growth stocks, on balance, have dramatically outperformed value stocks since the last major financial crisis. Historically low federal fund rates (the rate at which banks lend to one another), combined with enormous levels of fiscal stimulus by the U.S. government, were the main drivers behind this unprecedented 14-year-long bull run in growth stocks.</p><p>But with the Federal Reserve poised to roll out a series of interest rate hikes this year, value stocks are probably going to outperform growth stocks for the foreseeable future. In fact, value stocks have already started trouncing growth stocks, in terms of their total return on capital, since the beginning of the fourth quarter of 2021.</p><p>With this powerful trend reversal in mind, investors may want to load up on high-quality value stocks during the opening weeks of 2022. Which value plays are the best buys right now? The dividend-paying pharmaceutical stocks <a href=\"https://laohu8.com/S/TAK\"><b>Takeda Pharmaceutical</b></a> and <a href=\"https://laohu8.com/S/VTRS\"><b>Viatris</b></a> are both currently trading at dirt-cheap valuations. Here&#39;s why investors may want to add these two drugmakers to their portfolios soon.</p><p><a href=\"https://laohu8.com/S/TAK\"><b>Takeda Pharmaceutical</b></a>: An incredibly cheap high-yield dividend stock</p><p>Japanese pharma giant Takeda was one of the few major drug manufacturers to lose ground during the 14-year-long bull market. Various clinical setbacks, upcoming patent expiries, a highly leveraged balance sheet due to itsacquisitionof the rare disease specialist Shire, and a lack of a franchise-level medication all weighed on its shares during this period. Takeda&#39;s shares, in fact, have lost almost a third of their value in just the past three years. However, the company&#39;s stock now appears primed for a major reversal for three key reasons.</p><p>First off, Takeda&#39;s Wave 1 clinical pipeline has started to generate some truly high-value commercial products recently. Late last year, for instance, the company scored two important U.S. regulatory approvals for the post-transplant cytomegalovirus infection drug Livtencity and the niche lung cancer medication Exkivity. Takeda believes these two drugs will help drive respectable levels of top-line growth all the way out to fiscal year 2030 and keep its ongoing deleveraging process on track.</p><p>Second, Takeda&#39;s stock is presently trading at 1.5 times fiscal year 2022 projected sales. That&#39;s easily one of the lower price-to-sales ratios in the major drug manufacturing space right now. Takeda, in effect, is a bona fide value stock. This ought to benefit the drugmaker&#39;s share price in the current value-oriented market.</p><p>Third, Takeda pays out a sky-high annualized dividend yield of 5.6% right now. The company&#39;s stellar yield is also well-funded, evinced by its fairly low payout ratio of 59.4%.</p><p>All told, Takeda&#39;s stock ought to shine as investors rotate into pure-play value stocks and away from riskier growth equities.</p><p><a href=\"https://laohu8.com/S/VTRS\"><b>Viatris</b></a>: Stability and a top dividend yield</p><p>Viatris is a generic and biosimilar drug company. Since itsformationa little over a year ago, the company&#39;s shares have fallen by over 10.4%. Viatris&#39; stock has so farfailed to exciteinvestors due to itsdebt-laden balance sheet, lack of clear-cut growth products, and rather modest long-term outlook. The company, after all, isn&#39;t expecting sustainable top-line growth until 2024.</p><p>Despite these headwinds, however, Viatris stock should appeal to investors with an eye toward value. The long and short of it is that Viatris&#39; stock is among the absolute cheapest within the realm of dividend-paying pharma stocks right now. Underscoring this point, the drugmaker&#39;s shares are presently trading at less than one time forward-looking sales. What&#39;s more, Viatris currently offers shareholders an above-average yield -- relative to its peer group -- of 3.29% on an annualized basis.</p><p>So while Viatris stock isn&#39;t going to make shareholders rich anytime soon, this pharma stock does come across as a highly safe investing vehicle, thanks to its bargain bin valuation and attractive dividend yield. And Viatris&#39; top-notch margin of safety should prove to be a winning feature in this risk-averse market.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Dirt-Cheap Value Stocks to Buy Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Dirt-Cheap Value Stocks to Buy Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-30 10:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/29/2-dirt-cheap-value-stocks-to-buy-now/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Growth stocks, on balance, have dramatically outperformed value stocks since the last major financial crisis. Historically low federal fund rates (the rate at which banks lend to one another), ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/29/2-dirt-cheap-value-stocks-to-buy-now/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VTRS":"Viatris Inc.","TAK":"武田制药"},"source_url":"https://www.fool.com/investing/2022/01/29/2-dirt-cheap-value-stocks-to-buy-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1191140677","content_text":"Growth stocks, on balance, have dramatically outperformed value stocks since the last major financial crisis. Historically low federal fund rates (the rate at which banks lend to one another), combined with enormous levels of fiscal stimulus by the U.S. government, were the main drivers behind this unprecedented 14-year-long bull run in growth stocks.But with the Federal Reserve poised to roll out a series of interest rate hikes this year, value stocks are probably going to outperform growth stocks for the foreseeable future. In fact, value stocks have already started trouncing growth stocks, in terms of their total return on capital, since the beginning of the fourth quarter of 2021.With this powerful trend reversal in mind, investors may want to load up on high-quality value stocks during the opening weeks of 2022. Which value plays are the best buys right now? The dividend-paying pharmaceutical stocks Takeda Pharmaceutical and Viatris are both currently trading at dirt-cheap valuations. Here's why investors may want to add these two drugmakers to their portfolios soon.Takeda Pharmaceutical: An incredibly cheap high-yield dividend stockJapanese pharma giant Takeda was one of the few major drug manufacturers to lose ground during the 14-year-long bull market. Various clinical setbacks, upcoming patent expiries, a highly leveraged balance sheet due to itsacquisitionof the rare disease specialist Shire, and a lack of a franchise-level medication all weighed on its shares during this period. Takeda's shares, in fact, have lost almost a third of their value in just the past three years. However, the company's stock now appears primed for a major reversal for three key reasons.First off, Takeda's Wave 1 clinical pipeline has started to generate some truly high-value commercial products recently. Late last year, for instance, the company scored two important U.S. regulatory approvals for the post-transplant cytomegalovirus infection drug Livtencity and the niche lung cancer medication Exkivity. Takeda believes these two drugs will help drive respectable levels of top-line growth all the way out to fiscal year 2030 and keep its ongoing deleveraging process on track.Second, Takeda's stock is presently trading at 1.5 times fiscal year 2022 projected sales. That's easily one of the lower price-to-sales ratios in the major drug manufacturing space right now. Takeda, in effect, is a bona fide value stock. This ought to benefit the drugmaker's share price in the current value-oriented market.Third, Takeda pays out a sky-high annualized dividend yield of 5.6% right now. The company's stellar yield is also well-funded, evinced by its fairly low payout ratio of 59.4%.All told, Takeda's stock ought to shine as investors rotate into pure-play value stocks and away from riskier growth equities.Viatris: Stability and a top dividend yieldViatris is a generic and biosimilar drug company. Since itsformationa little over a year ago, the company's shares have fallen by over 10.4%. Viatris' stock has so farfailed to exciteinvestors due to itsdebt-laden balance sheet, lack of clear-cut growth products, and rather modest long-term outlook. The company, after all, isn't expecting sustainable top-line growth until 2024.Despite these headwinds, however, Viatris stock should appeal to investors with an eye toward value. The long and short of it is that Viatris' stock is among the absolute cheapest within the realm of dividend-paying pharma stocks right now. Underscoring this point, the drugmaker's shares are presently trading at less than one time forward-looking sales. What's more, Viatris currently offers shareholders an above-average yield -- relative to its peer group -- of 3.29% on an annualized basis.So while Viatris stock isn't going to make shareholders rich anytime soon, this pharma stock does come across as a highly safe investing vehicle, thanks to its bargain bin valuation and attractive dividend yield. And Viatris' top-notch margin of safety should prove to be a winning feature in this risk-averse market.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9093894900,"gmtCreate":1643587080003,"gmtModify":1676533832854,"author":{"id":"4105706439484420","authorId":"4105706439484420","name":"Nasbhai","avatar":"https://community-static.tradeup.com/news/fcdb00dbd2f786506cbba6840138e5ff","vip":1,"crmLevel":6,"crmLevelSwitch":1,"idStr":"4105706439484420","authorIdStr":"4105706439484420"},"htmlText":"Still find it over-valued in a way though&nbsp;","listText":"Still find it over-valued in a way though&nbsp;","text":"Still find it over-valued in a way though","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093894900","repostId":1191140677,"repostType":4,"repost":{"id":"1191140677","kind":"news","pubTimestamp":1643509277,"share":"https://ttm.financial/m/news/1191140677?lang=&edition=fundamental","pubTime":"2022-01-30 10:21","market":"us","language":"en","title":"2 Dirt-Cheap Value Stocks to Buy Now","url":"https://stock-news.laohu8.com/highlight/detail?id=1191140677","media":"Motley Fool","summary":"Growth stocks, on balance, have dramatically outperformed value stocks since the last major financia","content":"<html><head></head><body><p>Growth stocks, on balance, have dramatically outperformed value stocks since the last major financial crisis. Historically low federal fund rates (the rate at which banks lend to one another), combined with enormous levels of fiscal stimulus by the U.S. government, were the main drivers behind this unprecedented 14-year-long bull run in growth stocks.</p><p>But with the Federal Reserve poised to roll out a series of interest rate hikes this year, value stocks are probably going to outperform growth stocks for the foreseeable future. In fact, value stocks have already started trouncing growth stocks, in terms of their total return on capital, since the beginning of the fourth quarter of 2021.</p><p>With this powerful trend reversal in mind, investors may want to load up on high-quality value stocks during the opening weeks of 2022. Which value plays are the best buys right now? The dividend-paying pharmaceutical stocks <a href=\"https://laohu8.com/S/TAK\"><b>Takeda Pharmaceutical</b></a> and <a href=\"https://laohu8.com/S/VTRS\"><b>Viatris</b></a> are both currently trading at dirt-cheap valuations. Here&#39;s why investors may want to add these two drugmakers to their portfolios soon.</p><p><a href=\"https://laohu8.com/S/TAK\"><b>Takeda Pharmaceutical</b></a>: An incredibly cheap high-yield dividend stock</p><p>Japanese pharma giant Takeda was one of the few major drug manufacturers to lose ground during the 14-year-long bull market. Various clinical setbacks, upcoming patent expiries, a highly leveraged balance sheet due to itsacquisitionof the rare disease specialist Shire, and a lack of a franchise-level medication all weighed on its shares during this period. Takeda&#39;s shares, in fact, have lost almost a third of their value in just the past three years. However, the company&#39;s stock now appears primed for a major reversal for three key reasons.</p><p>First off, Takeda&#39;s Wave 1 clinical pipeline has started to generate some truly high-value commercial products recently. Late last year, for instance, the company scored two important U.S. regulatory approvals for the post-transplant cytomegalovirus infection drug Livtencity and the niche lung cancer medication Exkivity. Takeda believes these two drugs will help drive respectable levels of top-line growth all the way out to fiscal year 2030 and keep its ongoing deleveraging process on track.</p><p>Second, Takeda&#39;s stock is presently trading at 1.5 times fiscal year 2022 projected sales. That&#39;s easily one of the lower price-to-sales ratios in the major drug manufacturing space right now. Takeda, in effect, is a bona fide value stock. This ought to benefit the drugmaker&#39;s share price in the current value-oriented market.</p><p>Third, Takeda pays out a sky-high annualized dividend yield of 5.6% right now. The company&#39;s stellar yield is also well-funded, evinced by its fairly low payout ratio of 59.4%.</p><p>All told, Takeda&#39;s stock ought to shine as investors rotate into pure-play value stocks and away from riskier growth equities.</p><p><a href=\"https://laohu8.com/S/VTRS\"><b>Viatris</b></a>: Stability and a top dividend yield</p><p>Viatris is a generic and biosimilar drug company. Since itsformationa little over a year ago, the company&#39;s shares have fallen by over 10.4%. Viatris&#39; stock has so farfailed to exciteinvestors due to itsdebt-laden balance sheet, lack of clear-cut growth products, and rather modest long-term outlook. The company, after all, isn&#39;t expecting sustainable top-line growth until 2024.</p><p>Despite these headwinds, however, Viatris stock should appeal to investors with an eye toward value. The long and short of it is that Viatris&#39; stock is among the absolute cheapest within the realm of dividend-paying pharma stocks right now. Underscoring this point, the drugmaker&#39;s shares are presently trading at less than one time forward-looking sales. What&#39;s more, Viatris currently offers shareholders an above-average yield -- relative to its peer group -- of 3.29% on an annualized basis.</p><p>So while Viatris stock isn&#39;t going to make shareholders rich anytime soon, this pharma stock does come across as a highly safe investing vehicle, thanks to its bargain bin valuation and attractive dividend yield. And Viatris&#39; top-notch margin of safety should prove to be a winning feature in this risk-averse market.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Dirt-Cheap Value Stocks to Buy Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Dirt-Cheap Value Stocks to Buy Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-30 10:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/29/2-dirt-cheap-value-stocks-to-buy-now/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Growth stocks, on balance, have dramatically outperformed value stocks since the last major financial crisis. Historically low federal fund rates (the rate at which banks lend to one another), ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/29/2-dirt-cheap-value-stocks-to-buy-now/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VTRS":"Viatris Inc.","TAK":"武田制药"},"source_url":"https://www.fool.com/investing/2022/01/29/2-dirt-cheap-value-stocks-to-buy-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1191140677","content_text":"Growth stocks, on balance, have dramatically outperformed value stocks since the last major financial crisis. Historically low federal fund rates (the rate at which banks lend to one another), combined with enormous levels of fiscal stimulus by the U.S. government, were the main drivers behind this unprecedented 14-year-long bull run in growth stocks.But with the Federal Reserve poised to roll out a series of interest rate hikes this year, value stocks are probably going to outperform growth stocks for the foreseeable future. In fact, value stocks have already started trouncing growth stocks, in terms of their total return on capital, since the beginning of the fourth quarter of 2021.With this powerful trend reversal in mind, investors may want to load up on high-quality value stocks during the opening weeks of 2022. Which value plays are the best buys right now? The dividend-paying pharmaceutical stocks Takeda Pharmaceutical and Viatris are both currently trading at dirt-cheap valuations. Here's why investors may want to add these two drugmakers to their portfolios soon.Takeda Pharmaceutical: An incredibly cheap high-yield dividend stockJapanese pharma giant Takeda was one of the few major drug manufacturers to lose ground during the 14-year-long bull market. Various clinical setbacks, upcoming patent expiries, a highly leveraged balance sheet due to itsacquisitionof the rare disease specialist Shire, and a lack of a franchise-level medication all weighed on its shares during this period. Takeda's shares, in fact, have lost almost a third of their value in just the past three years. However, the company's stock now appears primed for a major reversal for three key reasons.First off, Takeda's Wave 1 clinical pipeline has started to generate some truly high-value commercial products recently. Late last year, for instance, the company scored two important U.S. regulatory approvals for the post-transplant cytomegalovirus infection drug Livtencity and the niche lung cancer medication Exkivity. Takeda believes these two drugs will help drive respectable levels of top-line growth all the way out to fiscal year 2030 and keep its ongoing deleveraging process on track.Second, Takeda's stock is presently trading at 1.5 times fiscal year 2022 projected sales. That's easily one of the lower price-to-sales ratios in the major drug manufacturing space right now. Takeda, in effect, is a bona fide value stock. This ought to benefit the drugmaker's share price in the current value-oriented market.Third, Takeda pays out a sky-high annualized dividend yield of 5.6% right now. The company's stellar yield is also well-funded, evinced by its fairly low payout ratio of 59.4%.All told, Takeda's stock ought to shine as investors rotate into pure-play value stocks and away from riskier growth equities.Viatris: Stability and a top dividend yieldViatris is a generic and biosimilar drug company. Since itsformationa little over a year ago, the company's shares have fallen by over 10.4%. Viatris' stock has so farfailed to exciteinvestors due to itsdebt-laden balance sheet, lack of clear-cut growth products, and rather modest long-term outlook. The company, after all, isn't expecting sustainable top-line growth until 2024.Despite these headwinds, however, Viatris stock should appeal to investors with an eye toward value. The long and short of it is that Viatris' stock is among the absolute cheapest within the realm of dividend-paying pharma stocks right now. Underscoring this point, the drugmaker's shares are presently trading at less than one time forward-looking sales. What's more, Viatris currently offers shareholders an above-average yield -- relative to its peer group -- of 3.29% on an annualized basis.So while Viatris stock isn't going to make shareholders rich anytime soon, this pharma stock does come across as a highly safe investing vehicle, thanks to its bargain bin valuation and attractive dividend yield. And Viatris' top-notch margin of safety should prove to be a winning feature in this risk-averse market.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9093170263,"gmtCreate":1643582822555,"gmtModify":1676533832126,"author":{"id":"3559797724435605","authorId":"3559797724435605","name":"seejay","avatar":"https://community-static.tradeup.com/news/e8541e0f14af1bc21276c96f2853aeec","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3559797724435605","authorIdStr":"3559797724435605"},"htmlText":"Watchlist","listText":"Watchlist","text":"Watchlist","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093170263","repostId":1191140677,"repostType":4,"repost":{"id":"1191140677","kind":"news","pubTimestamp":1643509277,"share":"https://ttm.financial/m/news/1191140677?lang=&edition=fundamental","pubTime":"2022-01-30 10:21","market":"us","language":"en","title":"2 Dirt-Cheap Value Stocks to Buy Now","url":"https://stock-news.laohu8.com/highlight/detail?id=1191140677","media":"Motley Fool","summary":"Growth stocks, on balance, have dramatically outperformed value stocks since the last major financia","content":"<html><head></head><body><p>Growth stocks, on balance, have dramatically outperformed value stocks since the last major financial crisis. Historically low federal fund rates (the rate at which banks lend to one another), combined with enormous levels of fiscal stimulus by the U.S. government, were the main drivers behind this unprecedented 14-year-long bull run in growth stocks.</p><p>But with the Federal Reserve poised to roll out a series of interest rate hikes this year, value stocks are probably going to outperform growth stocks for the foreseeable future. In fact, value stocks have already started trouncing growth stocks, in terms of their total return on capital, since the beginning of the fourth quarter of 2021.</p><p>With this powerful trend reversal in mind, investors may want to load up on high-quality value stocks during the opening weeks of 2022. Which value plays are the best buys right now? The dividend-paying pharmaceutical stocks <a href=\"https://laohu8.com/S/TAK\"><b>Takeda Pharmaceutical</b></a> and <a href=\"https://laohu8.com/S/VTRS\"><b>Viatris</b></a> are both currently trading at dirt-cheap valuations. Here&#39;s why investors may want to add these two drugmakers to their portfolios soon.</p><p><a href=\"https://laohu8.com/S/TAK\"><b>Takeda Pharmaceutical</b></a>: An incredibly cheap high-yield dividend stock</p><p>Japanese pharma giant Takeda was one of the few major drug manufacturers to lose ground during the 14-year-long bull market. Various clinical setbacks, upcoming patent expiries, a highly leveraged balance sheet due to itsacquisitionof the rare disease specialist Shire, and a lack of a franchise-level medication all weighed on its shares during this period. Takeda&#39;s shares, in fact, have lost almost a third of their value in just the past three years. However, the company&#39;s stock now appears primed for a major reversal for three key reasons.</p><p>First off, Takeda&#39;s Wave 1 clinical pipeline has started to generate some truly high-value commercial products recently. Late last year, for instance, the company scored two important U.S. regulatory approvals for the post-transplant cytomegalovirus infection drug Livtencity and the niche lung cancer medication Exkivity. Takeda believes these two drugs will help drive respectable levels of top-line growth all the way out to fiscal year 2030 and keep its ongoing deleveraging process on track.</p><p>Second, Takeda&#39;s stock is presently trading at 1.5 times fiscal year 2022 projected sales. That&#39;s easily one of the lower price-to-sales ratios in the major drug manufacturing space right now. Takeda, in effect, is a bona fide value stock. This ought to benefit the drugmaker&#39;s share price in the current value-oriented market.</p><p>Third, Takeda pays out a sky-high annualized dividend yield of 5.6% right now. The company&#39;s stellar yield is also well-funded, evinced by its fairly low payout ratio of 59.4%.</p><p>All told, Takeda&#39;s stock ought to shine as investors rotate into pure-play value stocks and away from riskier growth equities.</p><p><a href=\"https://laohu8.com/S/VTRS\"><b>Viatris</b></a>: Stability and a top dividend yield</p><p>Viatris is a generic and biosimilar drug company. Since itsformationa little over a year ago, the company&#39;s shares have fallen by over 10.4%. Viatris&#39; stock has so farfailed to exciteinvestors due to itsdebt-laden balance sheet, lack of clear-cut growth products, and rather modest long-term outlook. The company, after all, isn&#39;t expecting sustainable top-line growth until 2024.</p><p>Despite these headwinds, however, Viatris stock should appeal to investors with an eye toward value. The long and short of it is that Viatris&#39; stock is among the absolute cheapest within the realm of dividend-paying pharma stocks right now. Underscoring this point, the drugmaker&#39;s shares are presently trading at less than one time forward-looking sales. What&#39;s more, Viatris currently offers shareholders an above-average yield -- relative to its peer group -- of 3.29% on an annualized basis.</p><p>So while Viatris stock isn&#39;t going to make shareholders rich anytime soon, this pharma stock does come across as a highly safe investing vehicle, thanks to its bargain bin valuation and attractive dividend yield. And Viatris&#39; top-notch margin of safety should prove to be a winning feature in this risk-averse market.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Dirt-Cheap Value Stocks to Buy Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Dirt-Cheap Value Stocks to Buy Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-30 10:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/29/2-dirt-cheap-value-stocks-to-buy-now/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Growth stocks, on balance, have dramatically outperformed value stocks since the last major financial crisis. Historically low federal fund rates (the rate at which banks lend to one another), ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/29/2-dirt-cheap-value-stocks-to-buy-now/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VTRS":"Viatris Inc.","TAK":"武田制药"},"source_url":"https://www.fool.com/investing/2022/01/29/2-dirt-cheap-value-stocks-to-buy-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1191140677","content_text":"Growth stocks, on balance, have dramatically outperformed value stocks since the last major financial crisis. Historically low federal fund rates (the rate at which banks lend to one another), combined with enormous levels of fiscal stimulus by the U.S. government, were the main drivers behind this unprecedented 14-year-long bull run in growth stocks.But with the Federal Reserve poised to roll out a series of interest rate hikes this year, value stocks are probably going to outperform growth stocks for the foreseeable future. In fact, value stocks have already started trouncing growth stocks, in terms of their total return on capital, since the beginning of the fourth quarter of 2021.With this powerful trend reversal in mind, investors may want to load up on high-quality value stocks during the opening weeks of 2022. Which value plays are the best buys right now? The dividend-paying pharmaceutical stocks Takeda Pharmaceutical and Viatris are both currently trading at dirt-cheap valuations. Here's why investors may want to add these two drugmakers to their portfolios soon.Takeda Pharmaceutical: An incredibly cheap high-yield dividend stockJapanese pharma giant Takeda was one of the few major drug manufacturers to lose ground during the 14-year-long bull market. Various clinical setbacks, upcoming patent expiries, a highly leveraged balance sheet due to itsacquisitionof the rare disease specialist Shire, and a lack of a franchise-level medication all weighed on its shares during this period. Takeda's shares, in fact, have lost almost a third of their value in just the past three years. However, the company's stock now appears primed for a major reversal for three key reasons.First off, Takeda's Wave 1 clinical pipeline has started to generate some truly high-value commercial products recently. Late last year, for instance, the company scored two important U.S. regulatory approvals for the post-transplant cytomegalovirus infection drug Livtencity and the niche lung cancer medication Exkivity. Takeda believes these two drugs will help drive respectable levels of top-line growth all the way out to fiscal year 2030 and keep its ongoing deleveraging process on track.Second, Takeda's stock is presently trading at 1.5 times fiscal year 2022 projected sales. That's easily one of the lower price-to-sales ratios in the major drug manufacturing space right now. Takeda, in effect, is a bona fide value stock. This ought to benefit the drugmaker's share price in the current value-oriented market.Third, Takeda pays out a sky-high annualized dividend yield of 5.6% right now. The company's stellar yield is also well-funded, evinced by its fairly low payout ratio of 59.4%.All told, Takeda's stock ought to shine as investors rotate into pure-play value stocks and away from riskier growth equities.Viatris: Stability and a top dividend yieldViatris is a generic and biosimilar drug company. Since itsformationa little over a year ago, the company's shares have fallen by over 10.4%. Viatris' stock has so farfailed to exciteinvestors due to itsdebt-laden balance sheet, lack of clear-cut growth products, and rather modest long-term outlook. The company, after all, isn't expecting sustainable top-line growth until 2024.Despite these headwinds, however, Viatris stock should appeal to investors with an eye toward value. The long and short of it is that Viatris' stock is among the absolute cheapest within the realm of dividend-paying pharma stocks right now. Underscoring this point, the drugmaker's shares are presently trading at less than one time forward-looking sales. What's more, Viatris currently offers shareholders an above-average yield -- relative to its peer group -- of 3.29% on an annualized basis.So while Viatris stock isn't going to make shareholders rich anytime soon, this pharma stock does come across as a highly safe investing vehicle, thanks to its bargain bin valuation and attractive dividend yield. And Viatris' top-notch margin of safety should prove to be a winning feature in this risk-averse market.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9093148697,"gmtCreate":1643581544084,"gmtModify":1676533831849,"author":{"id":"3586474193512687","authorId":"3586474193512687","name":"Aaronboy","avatar":"https://static.tigerbbs.com/875e45a6d6b604dfaa34ac175ccbbb29","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3586474193512687","authorIdStr":"3586474193512687"},"htmlText":"Good buy","listText":"Good buy","text":"Good buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093148697","repostId":1191140677,"repostType":4,"repost":{"id":"1191140677","kind":"news","pubTimestamp":1643509277,"share":"https://ttm.financial/m/news/1191140677?lang=&edition=fundamental","pubTime":"2022-01-30 10:21","market":"us","language":"en","title":"2 Dirt-Cheap Value Stocks to Buy Now","url":"https://stock-news.laohu8.com/highlight/detail?id=1191140677","media":"Motley Fool","summary":"Growth stocks, on balance, have dramatically outperformed value stocks since the last major financia","content":"<html><head></head><body><p>Growth stocks, on balance, have dramatically outperformed value stocks since the last major financial crisis. Historically low federal fund rates (the rate at which banks lend to one another), combined with enormous levels of fiscal stimulus by the U.S. government, were the main drivers behind this unprecedented 14-year-long bull run in growth stocks.</p><p>But with the Federal Reserve poised to roll out a series of interest rate hikes this year, value stocks are probably going to outperform growth stocks for the foreseeable future. In fact, value stocks have already started trouncing growth stocks, in terms of their total return on capital, since the beginning of the fourth quarter of 2021.</p><p>With this powerful trend reversal in mind, investors may want to load up on high-quality value stocks during the opening weeks of 2022. Which value plays are the best buys right now? The dividend-paying pharmaceutical stocks <a href=\"https://laohu8.com/S/TAK\"><b>Takeda Pharmaceutical</b></a> and <a href=\"https://laohu8.com/S/VTRS\"><b>Viatris</b></a> are both currently trading at dirt-cheap valuations. Here&#39;s why investors may want to add these two drugmakers to their portfolios soon.</p><p><a href=\"https://laohu8.com/S/TAK\"><b>Takeda Pharmaceutical</b></a>: An incredibly cheap high-yield dividend stock</p><p>Japanese pharma giant Takeda was one of the few major drug manufacturers to lose ground during the 14-year-long bull market. Various clinical setbacks, upcoming patent expiries, a highly leveraged balance sheet due to itsacquisitionof the rare disease specialist Shire, and a lack of a franchise-level medication all weighed on its shares during this period. Takeda&#39;s shares, in fact, have lost almost a third of their value in just the past three years. However, the company&#39;s stock now appears primed for a major reversal for three key reasons.</p><p>First off, Takeda&#39;s Wave 1 clinical pipeline has started to generate some truly high-value commercial products recently. Late last year, for instance, the company scored two important U.S. regulatory approvals for the post-transplant cytomegalovirus infection drug Livtencity and the niche lung cancer medication Exkivity. Takeda believes these two drugs will help drive respectable levels of top-line growth all the way out to fiscal year 2030 and keep its ongoing deleveraging process on track.</p><p>Second, Takeda&#39;s stock is presently trading at 1.5 times fiscal year 2022 projected sales. That&#39;s easily one of the lower price-to-sales ratios in the major drug manufacturing space right now. Takeda, in effect, is a bona fide value stock. This ought to benefit the drugmaker&#39;s share price in the current value-oriented market.</p><p>Third, Takeda pays out a sky-high annualized dividend yield of 5.6% right now. The company&#39;s stellar yield is also well-funded, evinced by its fairly low payout ratio of 59.4%.</p><p>All told, Takeda&#39;s stock ought to shine as investors rotate into pure-play value stocks and away from riskier growth equities.</p><p><a href=\"https://laohu8.com/S/VTRS\"><b>Viatris</b></a>: Stability and a top dividend yield</p><p>Viatris is a generic and biosimilar drug company. Since itsformationa little over a year ago, the company&#39;s shares have fallen by over 10.4%. Viatris&#39; stock has so farfailed to exciteinvestors due to itsdebt-laden balance sheet, lack of clear-cut growth products, and rather modest long-term outlook. The company, after all, isn&#39;t expecting sustainable top-line growth until 2024.</p><p>Despite these headwinds, however, Viatris stock should appeal to investors with an eye toward value. The long and short of it is that Viatris&#39; stock is among the absolute cheapest within the realm of dividend-paying pharma stocks right now. Underscoring this point, the drugmaker&#39;s shares are presently trading at less than one time forward-looking sales. What&#39;s more, Viatris currently offers shareholders an above-average yield -- relative to its peer group -- of 3.29% on an annualized basis.</p><p>So while Viatris stock isn&#39;t going to make shareholders rich anytime soon, this pharma stock does come across as a highly safe investing vehicle, thanks to its bargain bin valuation and attractive dividend yield. And Viatris&#39; top-notch margin of safety should prove to be a winning feature in this risk-averse market.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Dirt-Cheap Value Stocks to Buy Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Dirt-Cheap Value Stocks to Buy Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-30 10:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/29/2-dirt-cheap-value-stocks-to-buy-now/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Growth stocks, on balance, have dramatically outperformed value stocks since the last major financial crisis. Historically low federal fund rates (the rate at which banks lend to one another), ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/29/2-dirt-cheap-value-stocks-to-buy-now/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VTRS":"Viatris Inc.","TAK":"武田制药"},"source_url":"https://www.fool.com/investing/2022/01/29/2-dirt-cheap-value-stocks-to-buy-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1191140677","content_text":"Growth stocks, on balance, have dramatically outperformed value stocks since the last major financial crisis. Historically low federal fund rates (the rate at which banks lend to one another), combined with enormous levels of fiscal stimulus by the U.S. government, were the main drivers behind this unprecedented 14-year-long bull run in growth stocks.But with the Federal Reserve poised to roll out a series of interest rate hikes this year, value stocks are probably going to outperform growth stocks for the foreseeable future. In fact, value stocks have already started trouncing growth stocks, in terms of their total return on capital, since the beginning of the fourth quarter of 2021.With this powerful trend reversal in mind, investors may want to load up on high-quality value stocks during the opening weeks of 2022. Which value plays are the best buys right now? The dividend-paying pharmaceutical stocks Takeda Pharmaceutical and Viatris are both currently trading at dirt-cheap valuations. Here's why investors may want to add these two drugmakers to their portfolios soon.Takeda Pharmaceutical: An incredibly cheap high-yield dividend stockJapanese pharma giant Takeda was one of the few major drug manufacturers to lose ground during the 14-year-long bull market. Various clinical setbacks, upcoming patent expiries, a highly leveraged balance sheet due to itsacquisitionof the rare disease specialist Shire, and a lack of a franchise-level medication all weighed on its shares during this period. Takeda's shares, in fact, have lost almost a third of their value in just the past three years. However, the company's stock now appears primed for a major reversal for three key reasons.First off, Takeda's Wave 1 clinical pipeline has started to generate some truly high-value commercial products recently. Late last year, for instance, the company scored two important U.S. regulatory approvals for the post-transplant cytomegalovirus infection drug Livtencity and the niche lung cancer medication Exkivity. Takeda believes these two drugs will help drive respectable levels of top-line growth all the way out to fiscal year 2030 and keep its ongoing deleveraging process on track.Second, Takeda's stock is presently trading at 1.5 times fiscal year 2022 projected sales. That's easily one of the lower price-to-sales ratios in the major drug manufacturing space right now. Takeda, in effect, is a bona fide value stock. This ought to benefit the drugmaker's share price in the current value-oriented market.Third, Takeda pays out a sky-high annualized dividend yield of 5.6% right now. The company's stellar yield is also well-funded, evinced by its fairly low payout ratio of 59.4%.All told, Takeda's stock ought to shine as investors rotate into pure-play value stocks and away from riskier growth equities.Viatris: Stability and a top dividend yieldViatris is a generic and biosimilar drug company. Since itsformationa little over a year ago, the company's shares have fallen by over 10.4%. Viatris' stock has so farfailed to exciteinvestors due to itsdebt-laden balance sheet, lack of clear-cut growth products, and rather modest long-term outlook. The company, after all, isn't expecting sustainable top-line growth until 2024.Despite these headwinds, however, Viatris stock should appeal to investors with an eye toward value. The long and short of it is that Viatris' stock is among the absolute cheapest within the realm of dividend-paying pharma stocks right now. Underscoring this point, the drugmaker's shares are presently trading at less than one time forward-looking sales. What's more, Viatris currently offers shareholders an above-average yield -- relative to its peer group -- of 3.29% on an annualized basis.So while Viatris stock isn't going to make shareholders rich anytime soon, this pharma stock does come across as a highly safe investing vehicle, thanks to its bargain bin valuation and attractive dividend yield. And Viatris' top-notch margin of safety should prove to be a winning feature in this risk-averse market.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9093141503,"gmtCreate":1643581344239,"gmtModify":1676533831829,"author":{"id":"4104210445036030","authorId":"4104210445036030","name":"Ccchia","avatar":"https://community-static.tradeup.com/news/d69e11a239f8e8cde6cbd37227dd17f6","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4104210445036030","authorIdStr":"4104210445036030"},"htmlText":"Good&nbsp;","listText":"Good&nbsp;","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093141503","repostId":1191140677,"repostType":4,"repost":{"id":"1191140677","kind":"news","pubTimestamp":1643509277,"share":"https://ttm.financial/m/news/1191140677?lang=&edition=fundamental","pubTime":"2022-01-30 10:21","market":"us","language":"en","title":"2 Dirt-Cheap Value Stocks to Buy Now","url":"https://stock-news.laohu8.com/highlight/detail?id=1191140677","media":"Motley Fool","summary":"Growth stocks, on balance, have dramatically outperformed value stocks since the last major financia","content":"<html><head></head><body><p>Growth stocks, on balance, have dramatically outperformed value stocks since the last major financial crisis. Historically low federal fund rates (the rate at which banks lend to one another), combined with enormous levels of fiscal stimulus by the U.S. government, were the main drivers behind this unprecedented 14-year-long bull run in growth stocks.</p><p>But with the Federal Reserve poised to roll out a series of interest rate hikes this year, value stocks are probably going to outperform growth stocks for the foreseeable future. In fact, value stocks have already started trouncing growth stocks, in terms of their total return on capital, since the beginning of the fourth quarter of 2021.</p><p>With this powerful trend reversal in mind, investors may want to load up on high-quality value stocks during the opening weeks of 2022. Which value plays are the best buys right now? The dividend-paying pharmaceutical stocks <a href=\"https://laohu8.com/S/TAK\"><b>Takeda Pharmaceutical</b></a> and <a href=\"https://laohu8.com/S/VTRS\"><b>Viatris</b></a> are both currently trading at dirt-cheap valuations. Here&#39;s why investors may want to add these two drugmakers to their portfolios soon.</p><p><a href=\"https://laohu8.com/S/TAK\"><b>Takeda Pharmaceutical</b></a>: An incredibly cheap high-yield dividend stock</p><p>Japanese pharma giant Takeda was one of the few major drug manufacturers to lose ground during the 14-year-long bull market. Various clinical setbacks, upcoming patent expiries, a highly leveraged balance sheet due to itsacquisitionof the rare disease specialist Shire, and a lack of a franchise-level medication all weighed on its shares during this period. Takeda&#39;s shares, in fact, have lost almost a third of their value in just the past three years. However, the company&#39;s stock now appears primed for a major reversal for three key reasons.</p><p>First off, Takeda&#39;s Wave 1 clinical pipeline has started to generate some truly high-value commercial products recently. Late last year, for instance, the company scored two important U.S. regulatory approvals for the post-transplant cytomegalovirus infection drug Livtencity and the niche lung cancer medication Exkivity. Takeda believes these two drugs will help drive respectable levels of top-line growth all the way out to fiscal year 2030 and keep its ongoing deleveraging process on track.</p><p>Second, Takeda&#39;s stock is presently trading at 1.5 times fiscal year 2022 projected sales. That&#39;s easily one of the lower price-to-sales ratios in the major drug manufacturing space right now. Takeda, in effect, is a bona fide value stock. This ought to benefit the drugmaker&#39;s share price in the current value-oriented market.</p><p>Third, Takeda pays out a sky-high annualized dividend yield of 5.6% right now. The company&#39;s stellar yield is also well-funded, evinced by its fairly low payout ratio of 59.4%.</p><p>All told, Takeda&#39;s stock ought to shine as investors rotate into pure-play value stocks and away from riskier growth equities.</p><p><a href=\"https://laohu8.com/S/VTRS\"><b>Viatris</b></a>: Stability and a top dividend yield</p><p>Viatris is a generic and biosimilar drug company. Since itsformationa little over a year ago, the company&#39;s shares have fallen by over 10.4%. Viatris&#39; stock has so farfailed to exciteinvestors due to itsdebt-laden balance sheet, lack of clear-cut growth products, and rather modest long-term outlook. The company, after all, isn&#39;t expecting sustainable top-line growth until 2024.</p><p>Despite these headwinds, however, Viatris stock should appeal to investors with an eye toward value. The long and short of it is that Viatris&#39; stock is among the absolute cheapest within the realm of dividend-paying pharma stocks right now. Underscoring this point, the drugmaker&#39;s shares are presently trading at less than one time forward-looking sales. What&#39;s more, Viatris currently offers shareholders an above-average yield -- relative to its peer group -- of 3.29% on an annualized basis.</p><p>So while Viatris stock isn&#39;t going to make shareholders rich anytime soon, this pharma stock does come across as a highly safe investing vehicle, thanks to its bargain bin valuation and attractive dividend yield. And Viatris&#39; top-notch margin of safety should prove to be a winning feature in this risk-averse market.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Dirt-Cheap Value Stocks to Buy Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Dirt-Cheap Value Stocks to Buy Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-30 10:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/29/2-dirt-cheap-value-stocks-to-buy-now/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Growth stocks, on balance, have dramatically outperformed value stocks since the last major financial crisis. Historically low federal fund rates (the rate at which banks lend to one another), ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/29/2-dirt-cheap-value-stocks-to-buy-now/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VTRS":"Viatris Inc.","TAK":"武田制药"},"source_url":"https://www.fool.com/investing/2022/01/29/2-dirt-cheap-value-stocks-to-buy-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1191140677","content_text":"Growth stocks, on balance, have dramatically outperformed value stocks since the last major financial crisis. Historically low federal fund rates (the rate at which banks lend to one another), combined with enormous levels of fiscal stimulus by the U.S. government, were the main drivers behind this unprecedented 14-year-long bull run in growth stocks.But with the Federal Reserve poised to roll out a series of interest rate hikes this year, value stocks are probably going to outperform growth stocks for the foreseeable future. In fact, value stocks have already started trouncing growth stocks, in terms of their total return on capital, since the beginning of the fourth quarter of 2021.With this powerful trend reversal in mind, investors may want to load up on high-quality value stocks during the opening weeks of 2022. Which value plays are the best buys right now? The dividend-paying pharmaceutical stocks Takeda Pharmaceutical and Viatris are both currently trading at dirt-cheap valuations. Here's why investors may want to add these two drugmakers to their portfolios soon.Takeda Pharmaceutical: An incredibly cheap high-yield dividend stockJapanese pharma giant Takeda was one of the few major drug manufacturers to lose ground during the 14-year-long bull market. Various clinical setbacks, upcoming patent expiries, a highly leveraged balance sheet due to itsacquisitionof the rare disease specialist Shire, and a lack of a franchise-level medication all weighed on its shares during this period. Takeda's shares, in fact, have lost almost a third of their value in just the past three years. However, the company's stock now appears primed for a major reversal for three key reasons.First off, Takeda's Wave 1 clinical pipeline has started to generate some truly high-value commercial products recently. Late last year, for instance, the company scored two important U.S. regulatory approvals for the post-transplant cytomegalovirus infection drug Livtencity and the niche lung cancer medication Exkivity. Takeda believes these two drugs will help drive respectable levels of top-line growth all the way out to fiscal year 2030 and keep its ongoing deleveraging process on track.Second, Takeda's stock is presently trading at 1.5 times fiscal year 2022 projected sales. That's easily one of the lower price-to-sales ratios in the major drug manufacturing space right now. Takeda, in effect, is a bona fide value stock. This ought to benefit the drugmaker's share price in the current value-oriented market.Third, Takeda pays out a sky-high annualized dividend yield of 5.6% right now. The company's stellar yield is also well-funded, evinced by its fairly low payout ratio of 59.4%.All told, Takeda's stock ought to shine as investors rotate into pure-play value stocks and away from riskier growth equities.Viatris: Stability and a top dividend yieldViatris is a generic and biosimilar drug company. Since itsformationa little over a year ago, the company's shares have fallen by over 10.4%. Viatris' stock has so farfailed to exciteinvestors due to itsdebt-laden balance sheet, lack of clear-cut growth products, and rather modest long-term outlook. The company, after all, isn't expecting sustainable top-line growth until 2024.Despite these headwinds, however, Viatris stock should appeal to investors with an eye toward value. The long and short of it is that Viatris' stock is among the absolute cheapest within the realm of dividend-paying pharma stocks right now. Underscoring this point, the drugmaker's shares are presently trading at less than one time forward-looking sales. What's more, Viatris currently offers shareholders an above-average yield -- relative to its peer group -- of 3.29% on an annualized basis.So while Viatris stock isn't going to make shareholders rich anytime soon, this pharma stock does come across as a highly safe investing vehicle, thanks to its bargain bin valuation and attractive dividend yield. And Viatris' top-notch margin of safety should prove to be a winning feature in this risk-averse market.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9093154327,"gmtCreate":1643579891989,"gmtModify":1676533831710,"author":{"id":"3555043402922696","authorId":"3555043402922696","name":"逢場作戲又一日","avatar":"https://community-static.tradeup.com/news/6a5fbf2ceb7c7ee0399d41e6348dadf7","vip":1,"hat":"https://static.tigerbbs.com/4c5ceab71416b120bab4604c0754b52a","crmLevel":5,"crmLevelSwitch":1,"idStr":"3555043402922696","authorIdStr":"3555043402922696"},"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093154327","repostId":1191140677,"repostType":4,"repost":{"id":"1191140677","kind":"news","pubTimestamp":1643509277,"share":"https://ttm.financial/m/news/1191140677?lang=&edition=fundamental","pubTime":"2022-01-30 10:21","market":"us","language":"en","title":"2 Dirt-Cheap Value Stocks to Buy Now","url":"https://stock-news.laohu8.com/highlight/detail?id=1191140677","media":"Motley Fool","summary":"Growth stocks, on balance, have dramatically outperformed value stocks since the last major financia","content":"<html><head></head><body><p>Growth stocks, on balance, have dramatically outperformed value stocks since the last major financial crisis. Historically low federal fund rates (the rate at which banks lend to one another), combined with enormous levels of fiscal stimulus by the U.S. government, were the main drivers behind this unprecedented 14-year-long bull run in growth stocks.</p><p>But with the Federal Reserve poised to roll out a series of interest rate hikes this year, value stocks are probably going to outperform growth stocks for the foreseeable future. In fact, value stocks have already started trouncing growth stocks, in terms of their total return on capital, since the beginning of the fourth quarter of 2021.</p><p>With this powerful trend reversal in mind, investors may want to load up on high-quality value stocks during the opening weeks of 2022. Which value plays are the best buys right now? The dividend-paying pharmaceutical stocks <a href=\"https://laohu8.com/S/TAK\"><b>Takeda Pharmaceutical</b></a> and <a href=\"https://laohu8.com/S/VTRS\"><b>Viatris</b></a> are both currently trading at dirt-cheap valuations. Here&#39;s why investors may want to add these two drugmakers to their portfolios soon.</p><p><a href=\"https://laohu8.com/S/TAK\"><b>Takeda Pharmaceutical</b></a>: An incredibly cheap high-yield dividend stock</p><p>Japanese pharma giant Takeda was one of the few major drug manufacturers to lose ground during the 14-year-long bull market. Various clinical setbacks, upcoming patent expiries, a highly leveraged balance sheet due to itsacquisitionof the rare disease specialist Shire, and a lack of a franchise-level medication all weighed on its shares during this period. Takeda&#39;s shares, in fact, have lost almost a third of their value in just the past three years. However, the company&#39;s stock now appears primed for a major reversal for three key reasons.</p><p>First off, Takeda&#39;s Wave 1 clinical pipeline has started to generate some truly high-value commercial products recently. Late last year, for instance, the company scored two important U.S. regulatory approvals for the post-transplant cytomegalovirus infection drug Livtencity and the niche lung cancer medication Exkivity. Takeda believes these two drugs will help drive respectable levels of top-line growth all the way out to fiscal year 2030 and keep its ongoing deleveraging process on track.</p><p>Second, Takeda&#39;s stock is presently trading at 1.5 times fiscal year 2022 projected sales. That&#39;s easily one of the lower price-to-sales ratios in the major drug manufacturing space right now. Takeda, in effect, is a bona fide value stock. This ought to benefit the drugmaker&#39;s share price in the current value-oriented market.</p><p>Third, Takeda pays out a sky-high annualized dividend yield of 5.6% right now. The company&#39;s stellar yield is also well-funded, evinced by its fairly low payout ratio of 59.4%.</p><p>All told, Takeda&#39;s stock ought to shine as investors rotate into pure-play value stocks and away from riskier growth equities.</p><p><a href=\"https://laohu8.com/S/VTRS\"><b>Viatris</b></a>: Stability and a top dividend yield</p><p>Viatris is a generic and biosimilar drug company. Since itsformationa little over a year ago, the company&#39;s shares have fallen by over 10.4%. Viatris&#39; stock has so farfailed to exciteinvestors due to itsdebt-laden balance sheet, lack of clear-cut growth products, and rather modest long-term outlook. The company, after all, isn&#39;t expecting sustainable top-line growth until 2024.</p><p>Despite these headwinds, however, Viatris stock should appeal to investors with an eye toward value. The long and short of it is that Viatris&#39; stock is among the absolute cheapest within the realm of dividend-paying pharma stocks right now. Underscoring this point, the drugmaker&#39;s shares are presently trading at less than one time forward-looking sales. What&#39;s more, Viatris currently offers shareholders an above-average yield -- relative to its peer group -- of 3.29% on an annualized basis.</p><p>So while Viatris stock isn&#39;t going to make shareholders rich anytime soon, this pharma stock does come across as a highly safe investing vehicle, thanks to its bargain bin valuation and attractive dividend yield. And Viatris&#39; top-notch margin of safety should prove to be a winning feature in this risk-averse market.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Dirt-Cheap Value Stocks to Buy Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Dirt-Cheap Value Stocks to Buy Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-30 10:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/29/2-dirt-cheap-value-stocks-to-buy-now/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Growth stocks, on balance, have dramatically outperformed value stocks since the last major financial crisis. Historically low federal fund rates (the rate at which banks lend to one another), ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/29/2-dirt-cheap-value-stocks-to-buy-now/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VTRS":"Viatris Inc.","TAK":"武田制药"},"source_url":"https://www.fool.com/investing/2022/01/29/2-dirt-cheap-value-stocks-to-buy-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1191140677","content_text":"Growth stocks, on balance, have dramatically outperformed value stocks since the last major financial crisis. Historically low federal fund rates (the rate at which banks lend to one another), combined with enormous levels of fiscal stimulus by the U.S. government, were the main drivers behind this unprecedented 14-year-long bull run in growth stocks.But with the Federal Reserve poised to roll out a series of interest rate hikes this year, value stocks are probably going to outperform growth stocks for the foreseeable future. In fact, value stocks have already started trouncing growth stocks, in terms of their total return on capital, since the beginning of the fourth quarter of 2021.With this powerful trend reversal in mind, investors may want to load up on high-quality value stocks during the opening weeks of 2022. Which value plays are the best buys right now? The dividend-paying pharmaceutical stocks Takeda Pharmaceutical and Viatris are both currently trading at dirt-cheap valuations. Here's why investors may want to add these two drugmakers to their portfolios soon.Takeda Pharmaceutical: An incredibly cheap high-yield dividend stockJapanese pharma giant Takeda was one of the few major drug manufacturers to lose ground during the 14-year-long bull market. Various clinical setbacks, upcoming patent expiries, a highly leveraged balance sheet due to itsacquisitionof the rare disease specialist Shire, and a lack of a franchise-level medication all weighed on its shares during this period. Takeda's shares, in fact, have lost almost a third of their value in just the past three years. However, the company's stock now appears primed for a major reversal for three key reasons.First off, Takeda's Wave 1 clinical pipeline has started to generate some truly high-value commercial products recently. Late last year, for instance, the company scored two important U.S. regulatory approvals for the post-transplant cytomegalovirus infection drug Livtencity and the niche lung cancer medication Exkivity. Takeda believes these two drugs will help drive respectable levels of top-line growth all the way out to fiscal year 2030 and keep its ongoing deleveraging process on track.Second, Takeda's stock is presently trading at 1.5 times fiscal year 2022 projected sales. That's easily one of the lower price-to-sales ratios in the major drug manufacturing space right now. Takeda, in effect, is a bona fide value stock. This ought to benefit the drugmaker's share price in the current value-oriented market.Third, Takeda pays out a sky-high annualized dividend yield of 5.6% right now. The company's stellar yield is also well-funded, evinced by its fairly low payout ratio of 59.4%.All told, Takeda's stock ought to shine as investors rotate into pure-play value stocks and away from riskier growth equities.Viatris: Stability and a top dividend yieldViatris is a generic and biosimilar drug company. Since itsformationa little over a year ago, the company's shares have fallen by over 10.4%. Viatris' stock has so farfailed to exciteinvestors due to itsdebt-laden balance sheet, lack of clear-cut growth products, and rather modest long-term outlook. The company, after all, isn't expecting sustainable top-line growth until 2024.Despite these headwinds, however, Viatris stock should appeal to investors with an eye toward value. The long and short of it is that Viatris' stock is among the absolute cheapest within the realm of dividend-paying pharma stocks right now. Underscoring this point, the drugmaker's shares are presently trading at less than one time forward-looking sales. What's more, Viatris currently offers shareholders an above-average yield -- relative to its peer group -- of 3.29% on an annualized basis.So while Viatris stock isn't going to make shareholders rich anytime soon, this pharma stock does come across as a highly safe investing vehicle, thanks to its bargain bin valuation and attractive dividend yield. And Viatris' top-notch margin of safety should prove to be a winning feature in this risk-averse market.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9093152892,"gmtCreate":1643578964168,"gmtModify":1676533831652,"author":{"id":"4099442649801160","authorId":"4099442649801160","name":"jojoc","avatar":"https://static.tigerbbs.com/ccc8519a0bdc4ba6b43a9aa8afa0e63c","vip":1,"hat":"https://static.tigerbbs.com/b0a2963eb37c60c5d6d4a8dbcd266952","crmLevel":4,"crmLevelSwitch":1,"idStr":"4099442649801160","authorIdStr":"4099442649801160"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093152892","repostId":1191140677,"repostType":4,"repost":{"id":"1191140677","kind":"news","pubTimestamp":1643509277,"share":"https://ttm.financial/m/news/1191140677?lang=&edition=fundamental","pubTime":"2022-01-30 10:21","market":"us","language":"en","title":"2 Dirt-Cheap Value Stocks to Buy Now","url":"https://stock-news.laohu8.com/highlight/detail?id=1191140677","media":"Motley Fool","summary":"Growth stocks, on balance, have dramatically outperformed value stocks since the last major financia","content":"<html><head></head><body><p>Growth stocks, on balance, have dramatically outperformed value stocks since the last major financial crisis. Historically low federal fund rates (the rate at which banks lend to one another), combined with enormous levels of fiscal stimulus by the U.S. government, were the main drivers behind this unprecedented 14-year-long bull run in growth stocks.</p><p>But with the Federal Reserve poised to roll out a series of interest rate hikes this year, value stocks are probably going to outperform growth stocks for the foreseeable future. In fact, value stocks have already started trouncing growth stocks, in terms of their total return on capital, since the beginning of the fourth quarter of 2021.</p><p>With this powerful trend reversal in mind, investors may want to load up on high-quality value stocks during the opening weeks of 2022. Which value plays are the best buys right now? The dividend-paying pharmaceutical stocks <a href=\"https://laohu8.com/S/TAK\"><b>Takeda Pharmaceutical</b></a> and <a href=\"https://laohu8.com/S/VTRS\"><b>Viatris</b></a> are both currently trading at dirt-cheap valuations. Here&#39;s why investors may want to add these two drugmakers to their portfolios soon.</p><p><a href=\"https://laohu8.com/S/TAK\"><b>Takeda Pharmaceutical</b></a>: An incredibly cheap high-yield dividend stock</p><p>Japanese pharma giant Takeda was one of the few major drug manufacturers to lose ground during the 14-year-long bull market. Various clinical setbacks, upcoming patent expiries, a highly leveraged balance sheet due to itsacquisitionof the rare disease specialist Shire, and a lack of a franchise-level medication all weighed on its shares during this period. Takeda&#39;s shares, in fact, have lost almost a third of their value in just the past three years. However, the company&#39;s stock now appears primed for a major reversal for three key reasons.</p><p>First off, Takeda&#39;s Wave 1 clinical pipeline has started to generate some truly high-value commercial products recently. Late last year, for instance, the company scored two important U.S. regulatory approvals for the post-transplant cytomegalovirus infection drug Livtencity and the niche lung cancer medication Exkivity. Takeda believes these two drugs will help drive respectable levels of top-line growth all the way out to fiscal year 2030 and keep its ongoing deleveraging process on track.</p><p>Second, Takeda&#39;s stock is presently trading at 1.5 times fiscal year 2022 projected sales. That&#39;s easily one of the lower price-to-sales ratios in the major drug manufacturing space right now. Takeda, in effect, is a bona fide value stock. This ought to benefit the drugmaker&#39;s share price in the current value-oriented market.</p><p>Third, Takeda pays out a sky-high annualized dividend yield of 5.6% right now. The company&#39;s stellar yield is also well-funded, evinced by its fairly low payout ratio of 59.4%.</p><p>All told, Takeda&#39;s stock ought to shine as investors rotate into pure-play value stocks and away from riskier growth equities.</p><p><a href=\"https://laohu8.com/S/VTRS\"><b>Viatris</b></a>: Stability and a top dividend yield</p><p>Viatris is a generic and biosimilar drug company. Since itsformationa little over a year ago, the company&#39;s shares have fallen by over 10.4%. Viatris&#39; stock has so farfailed to exciteinvestors due to itsdebt-laden balance sheet, lack of clear-cut growth products, and rather modest long-term outlook. The company, after all, isn&#39;t expecting sustainable top-line growth until 2024.</p><p>Despite these headwinds, however, Viatris stock should appeal to investors with an eye toward value. The long and short of it is that Viatris&#39; stock is among the absolute cheapest within the realm of dividend-paying pharma stocks right now. Underscoring this point, the drugmaker&#39;s shares are presently trading at less than one time forward-looking sales. What&#39;s more, Viatris currently offers shareholders an above-average yield -- relative to its peer group -- of 3.29% on an annualized basis.</p><p>So while Viatris stock isn&#39;t going to make shareholders rich anytime soon, this pharma stock does come across as a highly safe investing vehicle, thanks to its bargain bin valuation and attractive dividend yield. And Viatris&#39; top-notch margin of safety should prove to be a winning feature in this risk-averse market.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Dirt-Cheap Value Stocks to Buy Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Dirt-Cheap Value Stocks to Buy Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-30 10:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/29/2-dirt-cheap-value-stocks-to-buy-now/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Growth stocks, on balance, have dramatically outperformed value stocks since the last major financial crisis. Historically low federal fund rates (the rate at which banks lend to one another), ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/29/2-dirt-cheap-value-stocks-to-buy-now/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VTRS":"Viatris Inc.","TAK":"武田制药"},"source_url":"https://www.fool.com/investing/2022/01/29/2-dirt-cheap-value-stocks-to-buy-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1191140677","content_text":"Growth stocks, on balance, have dramatically outperformed value stocks since the last major financial crisis. Historically low federal fund rates (the rate at which banks lend to one another), combined with enormous levels of fiscal stimulus by the U.S. government, were the main drivers behind this unprecedented 14-year-long bull run in growth stocks.But with the Federal Reserve poised to roll out a series of interest rate hikes this year, value stocks are probably going to outperform growth stocks for the foreseeable future. In fact, value stocks have already started trouncing growth stocks, in terms of their total return on capital, since the beginning of the fourth quarter of 2021.With this powerful trend reversal in mind, investors may want to load up on high-quality value stocks during the opening weeks of 2022. Which value plays are the best buys right now? The dividend-paying pharmaceutical stocks Takeda Pharmaceutical and Viatris are both currently trading at dirt-cheap valuations. Here's why investors may want to add these two drugmakers to their portfolios soon.Takeda Pharmaceutical: An incredibly cheap high-yield dividend stockJapanese pharma giant Takeda was one of the few major drug manufacturers to lose ground during the 14-year-long bull market. Various clinical setbacks, upcoming patent expiries, a highly leveraged balance sheet due to itsacquisitionof the rare disease specialist Shire, and a lack of a franchise-level medication all weighed on its shares during this period. Takeda's shares, in fact, have lost almost a third of their value in just the past three years. However, the company's stock now appears primed for a major reversal for three key reasons.First off, Takeda's Wave 1 clinical pipeline has started to generate some truly high-value commercial products recently. Late last year, for instance, the company scored two important U.S. regulatory approvals for the post-transplant cytomegalovirus infection drug Livtencity and the niche lung cancer medication Exkivity. Takeda believes these two drugs will help drive respectable levels of top-line growth all the way out to fiscal year 2030 and keep its ongoing deleveraging process on track.Second, Takeda's stock is presently trading at 1.5 times fiscal year 2022 projected sales. That's easily one of the lower price-to-sales ratios in the major drug manufacturing space right now. Takeda, in effect, is a bona fide value stock. This ought to benefit the drugmaker's share price in the current value-oriented market.Third, Takeda pays out a sky-high annualized dividend yield of 5.6% right now. The company's stellar yield is also well-funded, evinced by its fairly low payout ratio of 59.4%.All told, Takeda's stock ought to shine as investors rotate into pure-play value stocks and away from riskier growth equities.Viatris: Stability and a top dividend yieldViatris is a generic and biosimilar drug company. Since itsformationa little over a year ago, the company's shares have fallen by over 10.4%. Viatris' stock has so farfailed to exciteinvestors due to itsdebt-laden balance sheet, lack of clear-cut growth products, and rather modest long-term outlook. The company, after all, isn't expecting sustainable top-line growth until 2024.Despite these headwinds, however, Viatris stock should appeal to investors with an eye toward value. The long and short of it is that Viatris' stock is among the absolute cheapest within the realm of dividend-paying pharma stocks right now. Underscoring this point, the drugmaker's shares are presently trading at less than one time forward-looking sales. What's more, Viatris currently offers shareholders an above-average yield -- relative to its peer group -- of 3.29% on an annualized basis.So while Viatris stock isn't going to make shareholders rich anytime soon, this pharma stock does come across as a highly safe investing vehicle, thanks to its bargain bin valuation and attractive dividend yield. And Viatris' top-notch margin of safety should prove to be a winning feature in this risk-averse market.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9093159152,"gmtCreate":1643573157347,"gmtModify":1676533831530,"author":{"id":"3582011723925907","authorId":"3582011723925907","name":"Rick13","avatar":"https://static.tigerbbs.com/2d3e47faeb6cb380146cd4f1415c29cf","vip":1,"crmLevel":7,"crmLevelSwitch":1,"idStr":"3582011723925907","authorIdStr":"3582011723925907"},"htmlText":"Good&nbsp;","listText":"Good&nbsp;","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093159152","repostId":1191140677,"repostType":2,"repost":{"id":"1191140677","kind":"news","pubTimestamp":1643509277,"share":"https://ttm.financial/m/news/1191140677?lang=&edition=fundamental","pubTime":"2022-01-30 10:21","market":"us","language":"en","title":"2 Dirt-Cheap Value Stocks to Buy Now","url":"https://stock-news.laohu8.com/highlight/detail?id=1191140677","media":"Motley Fool","summary":"Growth stocks, on balance, have dramatically outperformed value stocks since the last major financia","content":"<html><head></head><body><p>Growth stocks, on balance, have dramatically outperformed value stocks since the last major financial crisis. Historically low federal fund rates (the rate at which banks lend to one another), combined with enormous levels of fiscal stimulus by the U.S. government, were the main drivers behind this unprecedented 14-year-long bull run in growth stocks.</p><p>But with the Federal Reserve poised to roll out a series of interest rate hikes this year, value stocks are probably going to outperform growth stocks for the foreseeable future. In fact, value stocks have already started trouncing growth stocks, in terms of their total return on capital, since the beginning of the fourth quarter of 2021.</p><p>With this powerful trend reversal in mind, investors may want to load up on high-quality value stocks during the opening weeks of 2022. Which value plays are the best buys right now? The dividend-paying pharmaceutical stocks <a href=\"https://laohu8.com/S/TAK\"><b>Takeda Pharmaceutical</b></a> and <a href=\"https://laohu8.com/S/VTRS\"><b>Viatris</b></a> are both currently trading at dirt-cheap valuations. Here&#39;s why investors may want to add these two drugmakers to their portfolios soon.</p><p><a href=\"https://laohu8.com/S/TAK\"><b>Takeda Pharmaceutical</b></a>: An incredibly cheap high-yield dividend stock</p><p>Japanese pharma giant Takeda was one of the few major drug manufacturers to lose ground during the 14-year-long bull market. Various clinical setbacks, upcoming patent expiries, a highly leveraged balance sheet due to itsacquisitionof the rare disease specialist Shire, and a lack of a franchise-level medication all weighed on its shares during this period. Takeda&#39;s shares, in fact, have lost almost a third of their value in just the past three years. However, the company&#39;s stock now appears primed for a major reversal for three key reasons.</p><p>First off, Takeda&#39;s Wave 1 clinical pipeline has started to generate some truly high-value commercial products recently. Late last year, for instance, the company scored two important U.S. regulatory approvals for the post-transplant cytomegalovirus infection drug Livtencity and the niche lung cancer medication Exkivity. Takeda believes these two drugs will help drive respectable levels of top-line growth all the way out to fiscal year 2030 and keep its ongoing deleveraging process on track.</p><p>Second, Takeda&#39;s stock is presently trading at 1.5 times fiscal year 2022 projected sales. That&#39;s easily one of the lower price-to-sales ratios in the major drug manufacturing space right now. Takeda, in effect, is a bona fide value stock. This ought to benefit the drugmaker&#39;s share price in the current value-oriented market.</p><p>Third, Takeda pays out a sky-high annualized dividend yield of 5.6% right now. The company&#39;s stellar yield is also well-funded, evinced by its fairly low payout ratio of 59.4%.</p><p>All told, Takeda&#39;s stock ought to shine as investors rotate into pure-play value stocks and away from riskier growth equities.</p><p><a href=\"https://laohu8.com/S/VTRS\"><b>Viatris</b></a>: Stability and a top dividend yield</p><p>Viatris is a generic and biosimilar drug company. Since itsformationa little over a year ago, the company&#39;s shares have fallen by over 10.4%. Viatris&#39; stock has so farfailed to exciteinvestors due to itsdebt-laden balance sheet, lack of clear-cut growth products, and rather modest long-term outlook. The company, after all, isn&#39;t expecting sustainable top-line growth until 2024.</p><p>Despite these headwinds, however, Viatris stock should appeal to investors with an eye toward value. The long and short of it is that Viatris&#39; stock is among the absolute cheapest within the realm of dividend-paying pharma stocks right now. Underscoring this point, the drugmaker&#39;s shares are presently trading at less than one time forward-looking sales. What&#39;s more, Viatris currently offers shareholders an above-average yield -- relative to its peer group -- of 3.29% on an annualized basis.</p><p>So while Viatris stock isn&#39;t going to make shareholders rich anytime soon, this pharma stock does come across as a highly safe investing vehicle, thanks to its bargain bin valuation and attractive dividend yield. And Viatris&#39; top-notch margin of safety should prove to be a winning feature in this risk-averse market.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Dirt-Cheap Value Stocks to Buy Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Dirt-Cheap Value Stocks to Buy Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-30 10:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/29/2-dirt-cheap-value-stocks-to-buy-now/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Growth stocks, on balance, have dramatically outperformed value stocks since the last major financial crisis. Historically low federal fund rates (the rate at which banks lend to one another), ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/29/2-dirt-cheap-value-stocks-to-buy-now/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VTRS":"Viatris Inc.","TAK":"武田制药"},"source_url":"https://www.fool.com/investing/2022/01/29/2-dirt-cheap-value-stocks-to-buy-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1191140677","content_text":"Growth stocks, on balance, have dramatically outperformed value stocks since the last major financial crisis. Historically low federal fund rates (the rate at which banks lend to one another), combined with enormous levels of fiscal stimulus by the U.S. government, were the main drivers behind this unprecedented 14-year-long bull run in growth stocks.But with the Federal Reserve poised to roll out a series of interest rate hikes this year, value stocks are probably going to outperform growth stocks for the foreseeable future. In fact, value stocks have already started trouncing growth stocks, in terms of their total return on capital, since the beginning of the fourth quarter of 2021.With this powerful trend reversal in mind, investors may want to load up on high-quality value stocks during the opening weeks of 2022. Which value plays are the best buys right now? The dividend-paying pharmaceutical stocks Takeda Pharmaceutical and Viatris are both currently trading at dirt-cheap valuations. Here's why investors may want to add these two drugmakers to their portfolios soon.Takeda Pharmaceutical: An incredibly cheap high-yield dividend stockJapanese pharma giant Takeda was one of the few major drug manufacturers to lose ground during the 14-year-long bull market. Various clinical setbacks, upcoming patent expiries, a highly leveraged balance sheet due to itsacquisitionof the rare disease specialist Shire, and a lack of a franchise-level medication all weighed on its shares during this period. Takeda's shares, in fact, have lost almost a third of their value in just the past three years. However, the company's stock now appears primed for a major reversal for three key reasons.First off, Takeda's Wave 1 clinical pipeline has started to generate some truly high-value commercial products recently. Late last year, for instance, the company scored two important U.S. regulatory approvals for the post-transplant cytomegalovirus infection drug Livtencity and the niche lung cancer medication Exkivity. Takeda believes these two drugs will help drive respectable levels of top-line growth all the way out to fiscal year 2030 and keep its ongoing deleveraging process on track.Second, Takeda's stock is presently trading at 1.5 times fiscal year 2022 projected sales. That's easily one of the lower price-to-sales ratios in the major drug manufacturing space right now. Takeda, in effect, is a bona fide value stock. This ought to benefit the drugmaker's share price in the current value-oriented market.Third, Takeda pays out a sky-high annualized dividend yield of 5.6% right now. The company's stellar yield is also well-funded, evinced by its fairly low payout ratio of 59.4%.All told, Takeda's stock ought to shine as investors rotate into pure-play value stocks and away from riskier growth equities.Viatris: Stability and a top dividend yieldViatris is a generic and biosimilar drug company. Since itsformationa little over a year ago, the company's shares have fallen by over 10.4%. Viatris' stock has so farfailed to exciteinvestors due to itsdebt-laden balance sheet, lack of clear-cut growth products, and rather modest long-term outlook. The company, after all, isn't expecting sustainable top-line growth until 2024.Despite these headwinds, however, Viatris stock should appeal to investors with an eye toward value. The long and short of it is that Viatris' stock is among the absolute cheapest within the realm of dividend-paying pharma stocks right now. Underscoring this point, the drugmaker's shares are presently trading at less than one time forward-looking sales. What's more, Viatris currently offers shareholders an above-average yield -- relative to its peer group -- of 3.29% on an annualized basis.So while Viatris stock isn't going to make shareholders rich anytime soon, this pharma stock does come across as a highly safe investing vehicle, thanks to its bargain bin valuation and attractive dividend yield. And Viatris' top-notch margin of safety should prove to be a winning feature in this risk-averse market.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9093127129,"gmtCreate":1643567795296,"gmtModify":1676533831479,"author":{"id":"3578437374431441","authorId":"3578437374431441","name":"MNCoffee","avatar":"https://static.tigerbbs.com/1574b98e81022d53dfe703d67f405d4e","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3578437374431441","authorIdStr":"3578437374431441"},"htmlText":"wow","listText":"wow","text":"wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093127129","repostId":1191140677,"repostType":4,"repost":{"id":"1191140677","kind":"news","pubTimestamp":1643509277,"share":"https://ttm.financial/m/news/1191140677?lang=&edition=fundamental","pubTime":"2022-01-30 10:21","market":"us","language":"en","title":"2 Dirt-Cheap Value Stocks to Buy Now","url":"https://stock-news.laohu8.com/highlight/detail?id=1191140677","media":"Motley Fool","summary":"Growth stocks, on balance, have dramatically outperformed value stocks since the last major financia","content":"<html><head></head><body><p>Growth stocks, on balance, have dramatically outperformed value stocks since the last major financial crisis. Historically low federal fund rates (the rate at which banks lend to one another), combined with enormous levels of fiscal stimulus by the U.S. government, were the main drivers behind this unprecedented 14-year-long bull run in growth stocks.</p><p>But with the Federal Reserve poised to roll out a series of interest rate hikes this year, value stocks are probably going to outperform growth stocks for the foreseeable future. In fact, value stocks have already started trouncing growth stocks, in terms of their total return on capital, since the beginning of the fourth quarter of 2021.</p><p>With this powerful trend reversal in mind, investors may want to load up on high-quality value stocks during the opening weeks of 2022. Which value plays are the best buys right now? The dividend-paying pharmaceutical stocks <a href=\"https://laohu8.com/S/TAK\"><b>Takeda Pharmaceutical</b></a> and <a href=\"https://laohu8.com/S/VTRS\"><b>Viatris</b></a> are both currently trading at dirt-cheap valuations. Here&#39;s why investors may want to add these two drugmakers to their portfolios soon.</p><p><a href=\"https://laohu8.com/S/TAK\"><b>Takeda Pharmaceutical</b></a>: An incredibly cheap high-yield dividend stock</p><p>Japanese pharma giant Takeda was one of the few major drug manufacturers to lose ground during the 14-year-long bull market. Various clinical setbacks, upcoming patent expiries, a highly leveraged balance sheet due to itsacquisitionof the rare disease specialist Shire, and a lack of a franchise-level medication all weighed on its shares during this period. Takeda&#39;s shares, in fact, have lost almost a third of their value in just the past three years. However, the company&#39;s stock now appears primed for a major reversal for three key reasons.</p><p>First off, Takeda&#39;s Wave 1 clinical pipeline has started to generate some truly high-value commercial products recently. Late last year, for instance, the company scored two important U.S. regulatory approvals for the post-transplant cytomegalovirus infection drug Livtencity and the niche lung cancer medication Exkivity. Takeda believes these two drugs will help drive respectable levels of top-line growth all the way out to fiscal year 2030 and keep its ongoing deleveraging process on track.</p><p>Second, Takeda&#39;s stock is presently trading at 1.5 times fiscal year 2022 projected sales. That&#39;s easily one of the lower price-to-sales ratios in the major drug manufacturing space right now. Takeda, in effect, is a bona fide value stock. This ought to benefit the drugmaker&#39;s share price in the current value-oriented market.</p><p>Third, Takeda pays out a sky-high annualized dividend yield of 5.6% right now. The company&#39;s stellar yield is also well-funded, evinced by its fairly low payout ratio of 59.4%.</p><p>All told, Takeda&#39;s stock ought to shine as investors rotate into pure-play value stocks and away from riskier growth equities.</p><p><a href=\"https://laohu8.com/S/VTRS\"><b>Viatris</b></a>: Stability and a top dividend yield</p><p>Viatris is a generic and biosimilar drug company. Since itsformationa little over a year ago, the company&#39;s shares have fallen by over 10.4%. Viatris&#39; stock has so farfailed to exciteinvestors due to itsdebt-laden balance sheet, lack of clear-cut growth products, and rather modest long-term outlook. The company, after all, isn&#39;t expecting sustainable top-line growth until 2024.</p><p>Despite these headwinds, however, Viatris stock should appeal to investors with an eye toward value. The long and short of it is that Viatris&#39; stock is among the absolute cheapest within the realm of dividend-paying pharma stocks right now. Underscoring this point, the drugmaker&#39;s shares are presently trading at less than one time forward-looking sales. What&#39;s more, Viatris currently offers shareholders an above-average yield -- relative to its peer group -- of 3.29% on an annualized basis.</p><p>So while Viatris stock isn&#39;t going to make shareholders rich anytime soon, this pharma stock does come across as a highly safe investing vehicle, thanks to its bargain bin valuation and attractive dividend yield. And Viatris&#39; top-notch margin of safety should prove to be a winning feature in this risk-averse market.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Dirt-Cheap Value Stocks to Buy Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Dirt-Cheap Value Stocks to Buy Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-30 10:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/29/2-dirt-cheap-value-stocks-to-buy-now/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Growth stocks, on balance, have dramatically outperformed value stocks since the last major financial crisis. Historically low federal fund rates (the rate at which banks lend to one another), ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/29/2-dirt-cheap-value-stocks-to-buy-now/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VTRS":"Viatris Inc.","TAK":"武田制药"},"source_url":"https://www.fool.com/investing/2022/01/29/2-dirt-cheap-value-stocks-to-buy-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1191140677","content_text":"Growth stocks, on balance, have dramatically outperformed value stocks since the last major financial crisis. Historically low federal fund rates (the rate at which banks lend to one another), combined with enormous levels of fiscal stimulus by the U.S. government, were the main drivers behind this unprecedented 14-year-long bull run in growth stocks.But with the Federal Reserve poised to roll out a series of interest rate hikes this year, value stocks are probably going to outperform growth stocks for the foreseeable future. In fact, value stocks have already started trouncing growth stocks, in terms of their total return on capital, since the beginning of the fourth quarter of 2021.With this powerful trend reversal in mind, investors may want to load up on high-quality value stocks during the opening weeks of 2022. Which value plays are the best buys right now? The dividend-paying pharmaceutical stocks Takeda Pharmaceutical and Viatris are both currently trading at dirt-cheap valuations. Here's why investors may want to add these two drugmakers to their portfolios soon.Takeda Pharmaceutical: An incredibly cheap high-yield dividend stockJapanese pharma giant Takeda was one of the few major drug manufacturers to lose ground during the 14-year-long bull market. Various clinical setbacks, upcoming patent expiries, a highly leveraged balance sheet due to itsacquisitionof the rare disease specialist Shire, and a lack of a franchise-level medication all weighed on its shares during this period. Takeda's shares, in fact, have lost almost a third of their value in just the past three years. However, the company's stock now appears primed for a major reversal for three key reasons.First off, Takeda's Wave 1 clinical pipeline has started to generate some truly high-value commercial products recently. Late last year, for instance, the company scored two important U.S. regulatory approvals for the post-transplant cytomegalovirus infection drug Livtencity and the niche lung cancer medication Exkivity. Takeda believes these two drugs will help drive respectable levels of top-line growth all the way out to fiscal year 2030 and keep its ongoing deleveraging process on track.Second, Takeda's stock is presently trading at 1.5 times fiscal year 2022 projected sales. That's easily one of the lower price-to-sales ratios in the major drug manufacturing space right now. Takeda, in effect, is a bona fide value stock. This ought to benefit the drugmaker's share price in the current value-oriented market.Third, Takeda pays out a sky-high annualized dividend yield of 5.6% right now. The company's stellar yield is also well-funded, evinced by its fairly low payout ratio of 59.4%.All told, Takeda's stock ought to shine as investors rotate into pure-play value stocks and away from riskier growth equities.Viatris: Stability and a top dividend yieldViatris is a generic and biosimilar drug company. Since itsformationa little over a year ago, the company's shares have fallen by over 10.4%. Viatris' stock has so farfailed to exciteinvestors due to itsdebt-laden balance sheet, lack of clear-cut growth products, and rather modest long-term outlook. The company, after all, isn't expecting sustainable top-line growth until 2024.Despite these headwinds, however, Viatris stock should appeal to investors with an eye toward value. The long and short of it is that Viatris' stock is among the absolute cheapest within the realm of dividend-paying pharma stocks right now. Underscoring this point, the drugmaker's shares are presently trading at less than one time forward-looking sales. What's more, Viatris currently offers shareholders an above-average yield -- relative to its peer group -- of 3.29% on an annualized basis.So while Viatris stock isn't going to make shareholders rich anytime soon, this pharma stock does come across as a highly safe investing vehicle, thanks to its bargain bin valuation and attractive dividend yield. And Viatris' top-notch margin of safety should prove to be a winning feature in this risk-averse market.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9093123966,"gmtCreate":1643560404450,"gmtModify":1676533831337,"author":{"id":"3576459018241155","authorId":"3576459018241155","name":"ckLai","avatar":"https://static.tigerbbs.com/23354f3443d8a51feae4f8b8a4f5458c","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3576459018241155","authorIdStr":"3576459018241155"},"htmlText":"Hi","listText":"Hi","text":"Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093123966","repostId":1191140677,"repostType":4,"repost":{"id":"1191140677","kind":"news","pubTimestamp":1643509277,"share":"https://ttm.financial/m/news/1191140677?lang=&edition=fundamental","pubTime":"2022-01-30 10:21","market":"us","language":"en","title":"2 Dirt-Cheap Value Stocks to Buy Now","url":"https://stock-news.laohu8.com/highlight/detail?id=1191140677","media":"Motley Fool","summary":"Growth stocks, on balance, have dramatically outperformed value stocks since the last major financia","content":"<html><head></head><body><p>Growth stocks, on balance, have dramatically outperformed value stocks since the last major financial crisis. Historically low federal fund rates (the rate at which banks lend to one another), combined with enormous levels of fiscal stimulus by the U.S. government, were the main drivers behind this unprecedented 14-year-long bull run in growth stocks.</p><p>But with the Federal Reserve poised to roll out a series of interest rate hikes this year, value stocks are probably going to outperform growth stocks for the foreseeable future. In fact, value stocks have already started trouncing growth stocks, in terms of their total return on capital, since the beginning of the fourth quarter of 2021.</p><p>With this powerful trend reversal in mind, investors may want to load up on high-quality value stocks during the opening weeks of 2022. Which value plays are the best buys right now? The dividend-paying pharmaceutical stocks <a href=\"https://laohu8.com/S/TAK\"><b>Takeda Pharmaceutical</b></a> and <a href=\"https://laohu8.com/S/VTRS\"><b>Viatris</b></a> are both currently trading at dirt-cheap valuations. Here&#39;s why investors may want to add these two drugmakers to their portfolios soon.</p><p><a href=\"https://laohu8.com/S/TAK\"><b>Takeda Pharmaceutical</b></a>: An incredibly cheap high-yield dividend stock</p><p>Japanese pharma giant Takeda was one of the few major drug manufacturers to lose ground during the 14-year-long bull market. Various clinical setbacks, upcoming patent expiries, a highly leveraged balance sheet due to itsacquisitionof the rare disease specialist Shire, and a lack of a franchise-level medication all weighed on its shares during this period. Takeda&#39;s shares, in fact, have lost almost a third of their value in just the past three years. However, the company&#39;s stock now appears primed for a major reversal for three key reasons.</p><p>First off, Takeda&#39;s Wave 1 clinical pipeline has started to generate some truly high-value commercial products recently. Late last year, for instance, the company scored two important U.S. regulatory approvals for the post-transplant cytomegalovirus infection drug Livtencity and the niche lung cancer medication Exkivity. Takeda believes these two drugs will help drive respectable levels of top-line growth all the way out to fiscal year 2030 and keep its ongoing deleveraging process on track.</p><p>Second, Takeda&#39;s stock is presently trading at 1.5 times fiscal year 2022 projected sales. That&#39;s easily one of the lower price-to-sales ratios in the major drug manufacturing space right now. Takeda, in effect, is a bona fide value stock. This ought to benefit the drugmaker&#39;s share price in the current value-oriented market.</p><p>Third, Takeda pays out a sky-high annualized dividend yield of 5.6% right now. The company&#39;s stellar yield is also well-funded, evinced by its fairly low payout ratio of 59.4%.</p><p>All told, Takeda&#39;s stock ought to shine as investors rotate into pure-play value stocks and away from riskier growth equities.</p><p><a href=\"https://laohu8.com/S/VTRS\"><b>Viatris</b></a>: Stability and a top dividend yield</p><p>Viatris is a generic and biosimilar drug company. Since itsformationa little over a year ago, the company&#39;s shares have fallen by over 10.4%. Viatris&#39; stock has so farfailed to exciteinvestors due to itsdebt-laden balance sheet, lack of clear-cut growth products, and rather modest long-term outlook. The company, after all, isn&#39;t expecting sustainable top-line growth until 2024.</p><p>Despite these headwinds, however, Viatris stock should appeal to investors with an eye toward value. The long and short of it is that Viatris&#39; stock is among the absolute cheapest within the realm of dividend-paying pharma stocks right now. Underscoring this point, the drugmaker&#39;s shares are presently trading at less than one time forward-looking sales. What&#39;s more, Viatris currently offers shareholders an above-average yield -- relative to its peer group -- of 3.29% on an annualized basis.</p><p>So while Viatris stock isn&#39;t going to make shareholders rich anytime soon, this pharma stock does come across as a highly safe investing vehicle, thanks to its bargain bin valuation and attractive dividend yield. And Viatris&#39; top-notch margin of safety should prove to be a winning feature in this risk-averse market.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Dirt-Cheap Value Stocks to Buy Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Dirt-Cheap Value Stocks to Buy Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-30 10:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/29/2-dirt-cheap-value-stocks-to-buy-now/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Growth stocks, on balance, have dramatically outperformed value stocks since the last major financial crisis. Historically low federal fund rates (the rate at which banks lend to one another), ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/29/2-dirt-cheap-value-stocks-to-buy-now/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VTRS":"Viatris Inc.","TAK":"武田制药"},"source_url":"https://www.fool.com/investing/2022/01/29/2-dirt-cheap-value-stocks-to-buy-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1191140677","content_text":"Growth stocks, on balance, have dramatically outperformed value stocks since the last major financial crisis. Historically low federal fund rates (the rate at which banks lend to one another), combined with enormous levels of fiscal stimulus by the U.S. government, were the main drivers behind this unprecedented 14-year-long bull run in growth stocks.But with the Federal Reserve poised to roll out a series of interest rate hikes this year, value stocks are probably going to outperform growth stocks for the foreseeable future. In fact, value stocks have already started trouncing growth stocks, in terms of their total return on capital, since the beginning of the fourth quarter of 2021.With this powerful trend reversal in mind, investors may want to load up on high-quality value stocks during the opening weeks of 2022. Which value plays are the best buys right now? The dividend-paying pharmaceutical stocks Takeda Pharmaceutical and Viatris are both currently trading at dirt-cheap valuations. Here's why investors may want to add these two drugmakers to their portfolios soon.Takeda Pharmaceutical: An incredibly cheap high-yield dividend stockJapanese pharma giant Takeda was one of the few major drug manufacturers to lose ground during the 14-year-long bull market. Various clinical setbacks, upcoming patent expiries, a highly leveraged balance sheet due to itsacquisitionof the rare disease specialist Shire, and a lack of a franchise-level medication all weighed on its shares during this period. Takeda's shares, in fact, have lost almost a third of their value in just the past three years. However, the company's stock now appears primed for a major reversal for three key reasons.First off, Takeda's Wave 1 clinical pipeline has started to generate some truly high-value commercial products recently. Late last year, for instance, the company scored two important U.S. regulatory approvals for the post-transplant cytomegalovirus infection drug Livtencity and the niche lung cancer medication Exkivity. Takeda believes these two drugs will help drive respectable levels of top-line growth all the way out to fiscal year 2030 and keep its ongoing deleveraging process on track.Second, Takeda's stock is presently trading at 1.5 times fiscal year 2022 projected sales. That's easily one of the lower price-to-sales ratios in the major drug manufacturing space right now. Takeda, in effect, is a bona fide value stock. This ought to benefit the drugmaker's share price in the current value-oriented market.Third, Takeda pays out a sky-high annualized dividend yield of 5.6% right now. The company's stellar yield is also well-funded, evinced by its fairly low payout ratio of 59.4%.All told, Takeda's stock ought to shine as investors rotate into pure-play value stocks and away from riskier growth equities.Viatris: Stability and a top dividend yieldViatris is a generic and biosimilar drug company. Since itsformationa little over a year ago, the company's shares have fallen by over 10.4%. Viatris' stock has so farfailed to exciteinvestors due to itsdebt-laden balance sheet, lack of clear-cut growth products, and rather modest long-term outlook. The company, after all, isn't expecting sustainable top-line growth until 2024.Despite these headwinds, however, Viatris stock should appeal to investors with an eye toward value. The long and short of it is that Viatris' stock is among the absolute cheapest within the realm of dividend-paying pharma stocks right now. Underscoring this point, the drugmaker's shares are presently trading at less than one time forward-looking sales. What's more, Viatris currently offers shareholders an above-average yield -- relative to its peer group -- of 3.29% on an annualized basis.So while Viatris stock isn't going to make shareholders rich anytime soon, this pharma stock does come across as a highly safe investing vehicle, thanks to its bargain bin valuation and attractive dividend yield. And Viatris' top-notch margin of safety should prove to be a winning feature in this risk-averse market.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":908,"commentSize":71,"repostSize":0,"favoriteSize":5,"likeStatus":false,"favoriteStatus":false}}